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Abstract 
 
Being one of the most rapidly advancing cancer imaging techniques in recent years, Positron 
Emission Tomography (PET) represents a standard of excellence with respect to sensitivity and 
resolution for the non-invasive in vivo molecular imaging of solid tumours via the detection of 
radiotracer molecules.  Amongst these radiotracers, radiolabelled fluorinated nucleosides such 
as 3’-Deoxy-3’-[18F]-fluorothymidine (18F-FLT) has been widely recognized as a key, specific 
biomarker for tumour cellular proliferation. Current methods for the commercial production of 
[18F]FLT are characterized by low overall yields and time-consuming high-performance liquid 
chromatography (HPLC) purification. These disadvantages could be rectified by the 
development of a fast, efficient synthetic route to FLT that could enhance the productivity and 
reduce the reaction time of the fluoridation step necessary for the synthesis of short-lived 
radioisotope, 18F (t1/2=110 min) installed nucleoside.   
This project focussed mainly on the development of a new efficient chemical synthetic route to 
FLT. The synthesis and in vitro evaluation of a series of pro-nucleotide (ProTide) analogues of 
FLT as new potential therapeutic agents was also carried out.   
Various studies regarding FLT synthesis have been carried out on the cold (non-radioactive) 19F 
and radioactive 18F isomer by varying and optimizing conditions for the incorporation of 
different protecting groups and also different fluoridation reactions by nucleophilic 
displacement.  
Further optimization studies were made for the fluoridation step and the synthesis of [18F]FLT- 
ProTide analogues as new diagnostic PET imaging agents by variation of different chemical 
parameters on the phosphoramidate group was attempted. 
The synthesis of 19F- FLT based ProTides as new therapeutic agents were initiated by the 
introduction of the phosphoramidate group at the 5’-position of the furanosyl group of 
thymidine under basic conditions followed by fluoridation to generate the desired analogues. 
In addition to that, biological evaluation of the newly developed 19F-FLT ProTide analogues for 
anti-HIV 1 and anti-HIV 2 activities was undertaken on CEM cells. The results in those models 
indicated that the synthesized compounds were less potent than the parent nucleoside FLT. 
However in TK- (HIV-2) cells, the analogues retained biological activity in contrast to FLT. 
This suggested that the FLT ProTides bypassed the first phosphorylation step. 
However, the therapeutic in vitro evaluation for anti-tumour activity on L1210, CEM and HeLa 
cells showed no significant activity. 
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1. Introduction 
	  
1.1. Biological aspects of fluorinated nucleosides  
For decades, modified nucleosides especially fluorinated ones, have been the subject of 
many medicinal studies due to their predicted potential activity as enzyme inhibitors 
resulting in mainly anti-tumour1 and anti-viral2 activities. Apart from the predominance 
of fluorinated nucleosides as therapeutics, the role of some fluorinated nucleosides such 
as [18F]-fluorodeoxyglucose (FDG) and [18F]-3’-deoxy-3’-fluorothymidine (FLT, 
18Fluorine-labeled thymidine) as clinical diagnostic biomarkers in oncology has been 
widely recognized. These fluorinated nucleoside biomarkers find their primary cancer 
biomarker application in Positron Emission Tomography (PET) imaging, a nuclear 
medicine imaging technique that offers the ability to monitor tumour proliferation and 
other cancer hallmarks non-invasively in cancer patients.3 
 
1.1.1. Therapeutic aspects of fluorinated nucleosides 
Fluorinated nucleosides and their derivatives constitute a fundamentally important class 
of non-natural compounds that have been used in a wide variety of biological 
applications such as anti-viral and anti-tumour therapy, and as diagnostics. Natural 
nucleosides, which are the building blocks of both nucleic acids, deoxyribonucleic acid 
(DNA) and ribonucleic acid (RNA), are of fundamental importance in all living 
3	  
	  
systems.4,5 These nucleosides are composed of a nitrogen heterocycle base (Figure 1.1) 
linked to a sugar moiety (deoxyribose or ribose) by a β-N-glycosidic bond. The nitrogen 
base is either a purine or pyrimidine. 
	  
	  
      Figure 1.1: Structures of ribose, 2’-deoxyribose nucleosides and nitrogen bases.	  
                                                                                                   
Adenine and guanine are purine bases, which are present in both DNA and RNA, as is 
the pyrimidine base cytosine. However, the pyrimidine base uracil occurs only in RNA 
whereas the pyrimidine base thymine is present only in DNA. Regarding the sugar 
moiety, it varies from DNA to RNA; i.e. the sugar unit present in DNA is a 2-
deoxyribose while in RNA it is a ribose sugar molecule (Figure 1.1).6 Many biological 
applications such as anticancer and antiviral activities have been implemented by 
inducing small modifications to the structures of the naturally occurring nucleosides. 
The structural modifications could take place at either the heterocyclic base ring and/or 
at the sugar. These nucleoside analogues are phosphorylated at the 5’-position to form 
4	  
	  
active nucleotides that can function as inhibitors of viral and cellular proliferation 
processes.7 The initial, rate-limiting phosphorylation step is carried out by cytosolic 
kinase enzymes such as thymidine kinase 1 (TK1) and deoxycytidine kinase (dCK), to 
form the nucleoside monophosphate. The biochemical substrate specificity of 
nucleosides for kinase enzymes varies. For instance, thymidine, 1 and its analogues such 
as azidothymidine (AZT), 2 are substrates for TK1, while cytidine, 3 and its analogues 
such as gemcitabine, 4 are substrates for dCK.  
 
	  
	  
Figure 1.2: The nucleosides thymidine (1) and cytidine (3) with their respective 
analogues, AZT (2) and gemcitabine (4). 
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The monophosphorylation of nucleosides leads to the trapping of charged nucleotides 
inside the cellular cytoplasm. Since nucleosides are hydrophilic and diffuse slowly 
across cell membranes, cells have evolved a complex transport system consisting of 
multiple carrier proteins called nucleoside transporters (NTs) to facilitate the cellular 
uptake of these nucleoside analogues for nucleotide biosynthesis. The physiological 
roles of these transporters include the salvaging of DNA and RNA synthetic precursors.8 
Consecutively, the nucleoside monophosphates are further phosphorylated by kinases to 
form their respective diphosphates and finally the triphosphates which participate in the 
DNA and RNA biosynthesis.  
 
1.1.1.1. Impact of Fluorine Substitution 
Although fluorine is the most abundant halogen found on earth, it occurs extremely 
rarely in biologically active natural products and is completely absent in biomolecules 
such as nucleotides or nucleosides.9 Nature must have found it difficult to incorporate 
fluorine into naturally occurring molecules, perhaps because of the very strong energy 
of solvation of fluoride ions in water.10 However, many non-natural organo-fluorine 
compounds with indispensable biological properties have been synthesized.11 The idea 
of introducing fluorine into nucleosides at a specific position has gained much 
appreciation in the pharmaceutical pipeline over the past few decades. This is mainly 
due to the positive influence of fluorine on the physicochemical, pharmacokinetic and 
pharmacological properties of the resulting compounds.12  
The selective introduction of fluorine into a bioactive nucleoside as an isosteric 
replacement for hydrogen or as an isopolar mimic of a hydroxyl group can change the 
6	  
	  
inherent biological, physical and chemical properties of the molecule dramatically. It is 
generally thought that when hydrogen is substituted by fluorine, it exerts minimal steric 
constraints at the receptor sites due to the slight difference in their sizes.13,14,15  
Being one of the strongest bonds in organic chemistry, carbon-fluorine bond formation 
would result in the increase in metabolic and thermal stability. The C-F bond is less 
susceptible to oxidative metabolism caused by liver enzymes such as cytochrome P450 
(CYP) and hence contributes to metabolic stability.16  Fluorine substitution has often 
resulted in the enhanced biological activity of drugs by improving binding affinity with 
the target enzyme or receptor.17, 18 Another major impact is the increased hydrophobicity 
or the lipophilicity of the resulting compounds leading to greater passive diffusion of 
drugs across the membranes.19 As a matter of fact, these important properties are still 
being exploited in cutting edge research for the design and discovery of novel potential 
fluorinated nucleoside drug candidates.  
When nucleophilic fluorine substitution occurs at the 2’- or 3’-position of the bioactive 
nucleoside furanosyl (sugar) unit replacing hydrogen or the hydroxyl group, the 
chemical and biological stability of the nucleoside analogues are known to increase, 
since the strength of the resultant C-F bond is much greater than the C-H and C-O 
bonds. In particular, target binding activity can be exceeded in an acidic environment 
since the C-F bond is a hydrogen bond acceptor.20 In addition to this factor; metabolic 
stability is another favourable effect that results from this phenomenon.21 
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1.1.1.2. Antitumour activity of fluorinated nucleosides 
Fluorinated nucleosides are well documented and explored as potential anti-cancer 
agents.22 Studies suggest that the induction of apoptosis is the final pathway through 
which these drugs exert their anti-tumour activity.23 These nucleoside analogues mimic 
natural nucleosides in terms of uptake and metabolism. Further, these molecules can be 
incorporated into newly synthesized DNA resulting in chain termination. Some of these 
drugs also inhibit key enzymes involved in the biosynthesis of DNA and RNA 
synthesis, such as polymerases, leading to the activation of apoptosis by the anti-cancer 
agent. Some of the most relevant anticancer fluorinated nucleosides are shown in Figure 
1.3.24 Recent studies indicated the importance of one of the fluorinated nucleosides, 
clofarabine (2-chloro-2’-deoxy-fluoro-β-D-arabinofuranosyladenine), 5 as a new-
generation nucleoside analogue developed for acute lymphoblastic leukemia (ALL).25 It 
exerts its anti-cancer effect by inducing apoptosis following blockade of DNA synthesis 
as well as through inhibition of DNA repair. 
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Figure 1.3: Some important anti-cancer fluorinated nucleoside analogues such as 
gemcitabine (4), clofarabine (5), fludarabine (6), fludarabine monophosphate (7) and  
5-fluorouracil (5-FU, 8).24 
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Clofarabine is a new generation nucleoside anticancer agent structurally related to the 
nucleoside, fludarabine, 6.26 The nucleotide monophosphate derivative of 6, fludarabine 
phosphate, 7 is a water-soluble prodrug that is rapidly dephosphorylated to 2-fluoro-
vidarabine. Subsequently, it is transported actively into cells and rephosphorylated via 
deoxycytidine kinase to the active triphosphate derivative 2F-ara-adenosine triphosphate 
(2F-ara-ATP). This derivative competitively inhibits DNA synthesis via inhibition of 
DNA polymerase, ribonucleotide reductase, DNA primase and DNA ligase; hence 
preventing elongation of DNA strands through its direct incorporation into DNA as a 
fraudulent nucleotide.27,28 However, the degree of inhibition of these enzymes is 
stronger in the case of clofarabine. An illustration of the clofarabine mechanism of 
action that is reproduced from Bonate et al. Nat Rev Drug Discovery is shown in Figure 
1.4.26 The rate-limiting mono phosphorylation step of clofarabine is substantially more 
efficient than that of fludarabine.29 Additionally, the intracellular retention of 
clofarabine triphosphate in acute myeloid leukemia is longer than that of fludarabine, 
which contributes to the higher potency of clofarabine as an anti-cancer agent.30 In 
recent years, the combination of radiotherapy and chemotherapy has emerged as a 
potential tool in cancer therapy. The current experimental evidence showed that a 
moderate dose of clofarabine along with radiotherapy led to a significant inhibition of 
tumour growth.31 
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Figure 1.4: Clofarabine, which crosses the cell membrane by both diffusion and NT 
facilitated active transport, is monophosphorylated by dCK and by further 
phosphorylations, the active clofarabine triphosphate is formed. The triphosphate 
terminates DNA chain elongation and constricts repair through its incorporation into the 
DNA chain by competitive inhibition of DNA polymerases. It also inhibits 
ribonucleotide reductase (RNR) hindering the formation of deoxynucleotide 
triphosphates which are DNA precursors, and induces apoptosis through direct and 
indirect action on mitochondria by releasing cytochrome c and other apoptotic signals 
triggering cell death.26  
The well known 5-fluorouracil (5-FU), 8 which has been used in cancer treatment for 
more than 60 years, was first synthesized in 1957 by Heidelberger et al. as an 
antimetabolite.32 The active form is a uridine 5’-phosphate analogue, which is generated 
11	  
	  
in vivo. This prodrug is an active inhibitor of the enzyme, thymidylate synthase (TS) 
that converts 2’-deoxyuridine-5’-monophosphate (dUMP) to 2’-deoxythymidine-5’-
monophosphate (dTMP) via C5-methylation and thus blocks the formation of dTMP, 
which is a building block for DNA-synthesis and repair.33 5-FU has been extensively 
used for skin cancer treatments and a variety of solid tumours such as breast, colorectal 
and gastric tumours. Unfortunately, it has been found to cause neurotoxic and 
cardiotoxic side effects deriving from the lack of selectivity of 5-FU towards tumours 
and can lead to resistance by the excess production of dUMP in the cell to compete with 
the drug for the active site. 
Another milestone in anti-cancer fluorinated nucleoside therapeutics is the development 
of gemcitabine (2’,2’-difluorodeoxycytidine, dFdC), 4 by Eli Lilly in 1996 with a broad 
spectrum of activities against solid tumours such as pancreatic and breast cancers. Once 
transported into the cell, the pro-drug gemcitabine must be phosphorylated by the 
enzyme dCK to form the active species. The incorporation of the phosphates of 4 into 
DNA is considered to be the major mechanism by which cell death is caused and hence 
obstructing DNA synthesis by inhibiting DNA polymerases. 34 
 
1.1.1.3. Antiviral activity of fluorinated nucleosides 
The first anti-HIV (human immunodeficiency virus) nucleoside drug that was clinically 
approved for the treatment of AIDS (acquired immunodeficiency syndrome) was AZT 
(Azidothymidine/ Zidovudine), which is a nucleoside analogue that inhibits the 
functioning of HIV reverse transcriptase (RT).35 Since the development of AZT, there 
12	  
	  
has been extensive research into identifying nucleoside based compounds with good 
inhibitory activities of HIV reverse transcriptase and such compounds are classified as 
nucleoside reverse transcriptase inhibitors (NRTIs). The NRTIs include those 
compounds which can mimic endogenous pyrimidine or purine nucleosides, and all of 
them require intracellular phosphorylations to their respective triphosphates for 
therapeutic activity.36 
	  
	  
Figure 1.5: Some of the most potent anti-viral fluorinated nucleosides such as L-FMAU 
(1-[2-fluoro-5-methyl-beta-L-arabino-furanosyl]uracil, 9),  FLT (3’-fluoro-3’-
13	  
	  
deoxythymidine, 10), 3’-FddG (3’-fluoro-2’,3’-dideoxyguanosine, 11), 3’-FddU (3’-
fluoro-2’,3’-dideoxyuridine, 12) and 3’-FddC (3’-fluoro-2’,3’-dideoxycytidine, 13).37, 38 
The presence of a fluoro group in NRTIs makes them unique in terms of their chemical, 
biological and structural properties.  
The active fluorinated nucleotide triphosphate moiety is incorporated into the growing 
DNA by cellular polymerases. Mostly, when fluorine is substituted at the 3’-position of 
the nucleosides, it often leads to compounds imparting good antiviral activities as a 
result of the DNA chain termination effect that the absence of the 3’-hydroxyl group 
causes. As most of the NRTIs follow the same mechanism of inhibition of the HIV 
reverse transcriptase, a representative schematic diagram (Figure 1.6) illustrating the 
mechanism of action of 3’-FddC, 13 that is reproduced from J Clin Vir by De Clercq is 
given below.37 
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Figure 1.6: 3’FddC is phosphorylated by deoxycytidine kinase (dCK), deoxycytidine 
monophosphate kinase (dCMPK) and nucleotide diphosphate kinase (NDPK) to form 
FddC-monophosphate, FddC-diphosphate and the active FddC-triphosphate 
respectively. The viral enzyme reverse transcriptase catalyses the transcription of the 
retroviral RNA into DNA. By implanting the NRTI, FddC into DNA, the elongation of 
the growing viral DNA double strand is terminated via RT inhibition.37  
It is worth noting that since the first phosphorylation step (monophosphorylation) of the 
nucleoside analogue is rate-limiting, certain therapeutic nucleosides exhibit poor 
antiviral activity due to the deprived monophosphorylation resulting from the 
hydrophilic nature of nucleosides. Consequently, their membrane permeability potential 
and bioavailability are lowered. Therefore, employing a prodrug strategy that could 
successfully deliver the nucleoside monophosphate analogues into cells by bypassing 
the rate-limiting monophosphorylation could boost the antiviral activity. Nowadays, 
15	  
	  
several prodrug strategies exist, that deliver nucleoside monophosphate analogues into 
cells and these are discussed in Chapter 4.  
L-FMAU, 9 (clevudine) is a 2’-fluorinated L-nucleoside derivative of thymidine with 
potent anti-HBV (hepatitis B virus) activity. It is an oral antiviral agent for the treatment 
of chronic HBV.38 Another clinically used antiviral drug is 3’-FddG, 11 the 3’-fluoro 
analogue of dideoxyguanosine that showed potent anti-HIV and anti-HBV activities in 
vitro.39 
3’-fluoro-3’-deoxythymidine, 10 (FLT/ alovudine) has more potent antiretroviral 
activity in vitro than AZT (zidovudine). The substitution of fluorine for the azido group 
at the 3’-position of the deoxyribose ring generated FLT that was up to ten times more 
potent than AZT in preclinical studies.40 FLT inhibits replication of highly NRTI-
resistant HIV strains in vitro initially tested in the early 1990s.41 However, dose-
dependent drug safety concerns resulted in the initial development of alovudine to be 
halted due to toxicity.42 One of the main aims of this research project was to apply the 
pro-nucleotide strategy (ProTide technology) on to FLT as elaborated in Chapter 4, in 
order to deliver the FLT monophosphate into target cells at high concentration with 
minimal toxicity. 
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1.1.2. Diagnostic aspects of fluorinated nucleosides 
The application of fluorinated nucleosides as non-invasive imaging biomarkers of 
tumour cellular proliferation has been widely acknowledged. Biomarkers are playing an 
increasing role in the evaluation and validation of drug actions.43 A biomarker is defined 
as a characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes or pharmacological responses to a 
therapeutic intervention.44 Non-invasive imaging biomarkers are the subset of 
biomarkers that are detectable and measurable through a variety of imaging technologies 
developed by health professionals and researchers to image in vivo body structures and 
functions for the purpose of disease diagnosis, staging, and drug discovery. The imaging 
techniques include x-ray diffraction, optical, ultrasound, radiographs, CT (Computed 
Tomography), PET (Positron Emission Tomography), SPECT (Single Photon Emission 
Computed Tomography) and MRI (Magnetic Resonance Imaging).45  
Each of these modalities has its own advantages and disadvantages, as well as unique 
applications. Although a greater spatial resolution is obtained with optical, X-ray and 
MRI studies, these techniques are inherently insensitive for tracer studies, requiring 
tracer concentrations of >10-3 molar. Whereas, for nuclear based imaging techniques, 
SPECT and PET require the use of radiopharmaceutical molecules that are labeled with 
radioactive nuclides and are injected at tracer concentrations of 10-11 molar for SPECT 
and 10-12 molar for PET respectively which would essentially have no pharmacologic 
effect. Therefore, PET emerges as a highly sensitive imaging technique. In combination 
with X-ray CT, PET is becoming an imaging modality of increasing demand.46 
17	  
	  
1.1.2.1. Positron Emission Tomography (PET) 
PET is currently an invaluable tool used frequently in oncology, providing diagnosis, 
monitoring of treatment response, and imaging of tumour metabolic pathways.47 The 
ability to image and measure biological and/or biochemical processes in a non-invasive 
manner could be of great value; especially at the stage of diagnosis and treatment of 
malignancies in the case of cancer and PET is rapidly becoming the imaging technique 
of choice.48,49 Further evidence of the emerging importance of PET is provided by the 
continuing development of new PET centres at major hospital sites in UK, such as the 
Wolfson Brain Imaging Centre in Cambridge, Wolfson Molecular Imaging Centre in 
Manchester and PETIC at the University Hospital of Wales (established in 2009). The 
first medical application of positron emitters was reported more than 50 years ago in 
1951 by Sweet at Massachusetts General Hospital, in which a simple probe was used to 
localize brain tumours with the use of coincidence detectors.50 
 
1.1.2.1.1. Basic Principles of PET 
This technology relies mainly on positron emitting short-lived radionuclides, which are 
radioactive atoms/isotopes that consist of an unstable nucleus undergoing spontaneous 
radioactive decay by the emission of γ rays and/or subatomic particles; hence achieving 
stability.  
Positron emission is a type of beta decay characteristic of low or medium mass neutron-
deficient nuclei. So in this radioactive decay, a proton (p) is converted to a neutron (n), a 
positron (e+) and a neutrino (ν) as shown in the formula below: 
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Positron emission          p      n  + e + +  ν 
Positron emission occurs only if an energy of 1022 keV or greater is available; 
otherwise electron capture (EC) would take place. 
Electron capture      p  +  e -         n  + ν 
During positron emission, the emitted positron collides with the surrounding electron 
and as they are antiparticles, they annihilate each other. In the annihilation process, two 
gamma quanta of 511 keV are generated that travel in opposite directions at a relative 
angle of 180 0C and measured coincidently by a pair of detectors. These detector 
cameras, which are combined with powerful computing systems, convert the gamma- 
rays into electronic signals for data acquisition and image reconstruction and these 
consequently provide information about the distribution of the radiotracer in tissue.51 In 
Figure 1.7 that is reproduced from Diploma work by Heins, the basic principle of PET 
imaging is demonstrated.52 
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Figure 1.7: The basic principle of PET imaging.52 
 
 
1.1.2.1.2. PET radiotracers 
Conventionally, PET employs radiotracer molecules that are biomolecules such as 
glucose analogues, proteins or DNA-components (eg. thymidine) labeled with positron 
emitting radionuclides of fairly short half-lives. The most commonly used radionuclides 
are: 11C (t1/2 = 20 min), 13N (t1/2 = 10 min), 15O (t1/2 = 2 min), and 18F (t1/2 = 110 min). 
All these radioisotopes are produced by a cyclotron, which is ideally located as close as 
possible to the PET scanner because of the short half-lives of the positron-emitting 
radionuclides. Hence, amongst commonly used (non-metal) PET radioisotopes only 18F 
can be transported from its production site as a result of its longer half-life compared to 
others. 
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The most common way of producing 18F- ions inside the cyclotron is the 18O (p,n) 18F 
reaction, in which H218O (oxygen-18-enriched water (>90%)) acts as the target material 
to be bombarded with proton beams to generate the 18F- ion in water and a neutron as 
shown in Figure 1.8. The required radioactive fluoride ion is available for further 
reactions to produce 18F-based radiotracer molecules after separation from water. Since 
18F is generated as an anion, it is normally introduced into molecules via nucleophilic 
reactions. 
	  
Figure 1.8: Production of an 18F nucleus inside the cyclotron by the bombardment of a 
proton with oxygen-18-enriched water to form the radioactive 18F nucleus consisting of 
nine protons and nine neutrons with the release of a neutron. 
According to nature, carbon, oxygen, nitrogen, and hydrogen are the main elements of 
life and building blocks of nearly every molecule of biological importance. But since 
hydrogen has no radioactive isotope undergoing positron emission, the fluorine isotope 
is often used to replace the hydrogen atom for many positive reasons. The 18F isotope is 
mostly considered as an ideal positron emitter as its cyclotron production is efficient and 
high activity is generated. Its longer optimum half-life allows multi-step synthesis of 
their respective tracers, purification and shipment. High specific activity, which is the 
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amount of radioactivity per gram or mole; high positron yield (e+ 96.7%), low positron 
energy (635 keV), hence enabling image reconstruction at high resolution, are its 
additional advantages.51 Another important fact is that the presence of the small and 
highly electronegative fluorine isotope, can lead to a more metabolically stable 
radiotracer molecule. For these purposes, investigators in the field of nuclear medicine 
have been striving to develop effective 18F radiotracers for more than 30 years.49, 53 
When designing a novel radiotracer molecule, factors such as an appropriate target, high 
in vitro affinity and selectivity for target, reliable radiolabeling, target accessibility, and 
low non-specific binding have to be considered. Hence the ideal radiotracer should 
result in good signal to noise ratio in vivo, appropriate in vivo pharmacokinetics, 
distribution and pharmacology, use of low quantities of labeled metabolites and finally 
should exhibit sensitivity and selectivity towards the target.54 
Due to the relatively longer half-life of the positron emitting isotope fluorine-18 (t1/2= 
110 min), fluorinated PET probes have emerged to be more prevalent.55 The most 
widely used clinical PET tracer molecule to date is the 18F-labeled fluorodeoxyglucose 
([18F] FDG, 14) as seen in Figure 1.9. However, 18F-FDG has not satisfied the need for 
a specific indicator of tumour cellular proliferation although it is very effective in 
locating many types of human solid tumours.56 Once injected intravenously, this tracer 
molecule is transported into tumour cells and once internalised, 14 is rapidly and 
irreversibly phosphorylated by hexokinase. It cannot be further phosphorylated because 
of the presence of the fluorine atom and as a result 18F-FDG-5’-monophosphate is 
trapped intracellularly. Thus, an [18F] FDG PET image reveals those locations where 
glucose metabolic activity is highest.57  
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Figure 1.9: Some currently used clinical fluorinated PET biomarkers such as 18F-FDG 
([18F]-2’-fluorodeoxyglucose, 14), 18F-FLT ([18F]-3’-fluoro-3’-deoxythymidine, 15) and 
18F-FMAU ([18F]-1-[2’-fluoro-5-methyl-β-L-arabinofuranosyl]uracil, 16). 
 
Since 1998, the introduction of 3’-deoxy-3’-[18F]fluorothymidine ([18F]FLT, 15) has 
drawn much attention as a cellular proliferation imaging biomarker in oncology for the 
purpose of PET imaging. [18F]FLT, 15 is also one of the most commonly used 
fluorinated nucleoside PET tracer molecule and was developed as an alternative to the 
derivative [11C]thymidine in order to overcome the in vivo catabolism of thymidine.58 
The PET tracer molecule, 15 is subject to intracellular phosphorylation by the enzyme 
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thymidine kinase-1 (TK1), which is expressed during the DNA synthesis phase (S-
phase) of the cell cycle. Consequently, the resulting 18F-labeled thymidine 
monophosphate gets trapped within the proliferating cells. Thus it has been shown that 
the selective uptake of 15 by tumour cells reflects the cell proliferation rate better than 
the widely used tumour-imaging agent, [18F]FDG (14).59   Their selective uptake in 
proliferating tumour cells is thought to be based on two mechanisms which are either 
the over-expression of human nucleoside transporters (hNT 1) that aids in the transport 
of FLT across the tumour cell membranes or the increased activity of proliferation-
dependent thymidine kinase 1 enzyme that results in the FLT phosphorylation and 
accumulation of FLT monophosphates in tumour cells.60 
[18F]FLT has been reported to be inert to metabolic degradation unlike 18F FDG.61, 62 It 
has also been used to investigate various types of cancers for imaging tumour 
proliferation with PET and is currently in clinical use.63 Besides tumour imaging, this 
radiotracer has also proved to be very useful to measure early response to therapy, 
which has been performed in both animal models and humans.64,65 For the quantitative 
measurement of tumour cellular proliferation, [18F]FLT PET was found to be superior to 
that of [18F]FDG PET.66  
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1.2. Synthesis of 18F-labeled Nucleosides for PET Imaging 
1.2.1. Radioactive labeling with Fluorine-18 
Amongst the radioactive nuclides present in existing PET biomarkers, fluorine-18 (18F) 
has the most favourable nuclear properties and therefore it is the most widely used 
radioisotope for PET imaging. It has a relatively long half-life of 110 minutes compared 
to other positron-emitting radionuclides (e.g. 20 minutes for 11C) which allows fluorine 
to be produced in a regional centre and to be distributed to local hospitals, provided that 
the radiochemical synthesis of the tracer molecule is rapid and efficient. For example, 
transporting a 1 GBq dose of 18F activity gives a 250 MBq dose at a site four hours 
away. The half-life of 18F also provides sufficient decay time for imaging and 
pharmacokinetic studies to be conducted. The 18F radioisotope also gives the highest 
resolution PET images out of all the available positron emitters due to its relatively low 
positron energy (635 keV). In addition to that, both the high specific activity 
(radioactivity per gram of a radioactive material; units are Becquerel/gram or Bq/g) and 
high positron yield (β+ 96.7%) of the 18F radioisotope, make it an ideal positron emitter. 
Another advantage is that, the small and highly electronegative fluorine atom imparts 
some improved molecular properties to small molecules such as resistance to CYP-
induced metabolism. A list of available positron emitting isotopes for PET imaging has 
been provided in Table 1.1.67  
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Table 1.1. Positron-emitting isotopes for PET imaging67 
Isotope t1/2 Positron energy/ yield 
86Y 14.74 h 1254 keV (12.4 %) 
64Cu 12.7 h 653 keV (17.9 %) 
66Ga 9.4 h 4153 keV (49.3 %) 
18F 109.8 min 633 keV (96.7 %) 
11C 20.39 min 960 keV (99.8 %) 
13N 10 min 1199 keV (99.8 %) 
15O 2 min 1732 keV (99.8 %) 
 
It can be noted from Table 1.1 that transition metal isotopes such as 86Y and 64Cu have 
half-lives lasting for several hours, which may not be optimal as patients are exposed to 
a higher risk due to the prolonged exposure to radioactivity. Hence, these isotopes have 
not emerged as relevant in imaging biomolecules. 
However, there are certain practical limitations involved in the chemical synthesis of 
18F-labeled molecules. Most syntheses of non-radiolabeled fluorinated drug molecules 
(containing the natural 19F isomer) have the fluorine atom present at an early stage of 
synthesis for a multi-step process. Considering the longer exposure to radioactivity and 
the decay time of the fluorine isotope, 18F incorporation into molecules at an early stage 
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is not feasible for the multi-step synthesis of 18F-labeled compounds. The half-life of the 
positron-emitting 18F atom (110 minutes) means that its introduction has to be near the 
end of the synthetic sequence, while the speed of reaction and purification have to be 
efficient and GMP (good manufacturing practice) compliant if high quality patient PET 
data are to be obtained. In general, the final radiolabeled tracer molecule should be 
synthesized, purified and formulated to pharmaceutical (injectable) quality within the 
half-life of the PET isotope. 
 
1.2.1.1. Strategies for 18F Radiolabeling 
The variety of chemical methods by which the 18F radioactive nuclide can be introduced 
into target molecules is rather limited. The two distinct areas, into which the main 
synthetic strategies behind 18F labeling are crudely divided, are given below: 
i. direct fluorination, where the 18F isotope is incorporated “directly” into the target 
molecule in one step; and  
ii. indirect fluorination which utilizes 18F prosthetic groups and requires a multistep 
synthetic approach. 
These prosthetic groups are typically small 18F labeled alkyl or aryl groups that have 
reactive functional groups. They are exploited to react with more complex biological 
molecules, which are very difficult or unstable to undergo direct fluorination methods.67-
70 An example of indirect fluorination is the click reaction firstly adopted by Marik, 
Sutclife et al.71 for the preparation of 18F-labeled peptide fragments as shown in Scheme 
1.1. In this method, an 18F-labeled alkyne 18 was prepared by the 18F- nucleophilic 
substitution reaction of an alkyne tosylate 17. As conventional copper (I)-catalysed 1,3-
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dipolar cycloadditions of azides and alkynes require reaction times of several hours to 
obtain high yields, rapid syntheses of PET biomarkers may not be feasible. However, 
the vast stoichiometric excess of the CuI catalyst and azide compared to the [18F] alkyne 
18, resulted in good radiochemical yield (RCY: 54-99%) of the 18F-labeled peptide 19 
within 10 minutes at room temperature.71 
	  
Scheme 1.1: Formation of 18F-labeled peptide, 19 through the indirect 18F labeling of 
the prosthetic alkyne group, 18. 
 
The direct 18F labeling strategies can be subdivided into two main areas of fluorination, 
namely nucleophilic and electrophilic. Nevertheless, among these two methods, 
nucleophilic 18F-fluorination reactions have emerged to be more dominant and 
important due to their greater selectivity and capability to give radioactive compounds. 
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1.2.1.2. Electrophilic Fluorine-18 Labeling Reactions 
Nowadays, electrophilic 18F-fluorinations are less favoured for the synthesis of PET 
tracer molecules mainly for two reasons. First of all, the disadvantages associated with 
the use of electrophilic reagents such as 18F-F for labeling are considerable, as handling 
of fluorine poses significant safety issues resulting from the use of this highly toxic gas. 
Secondly, the high reactivity of 18F-F in electrophilic substitution reactions can result in 
unpredictable and unspecific mixtures (e.g. through low regioselectivities) of 18F-labeled 
products and hence the necessity of further product purification steps. It is also to be 
noted that the use of 18F-F leads to mixtures of 19F- and 18F-containing product resulting 
in variable radiochemical yields and low specific activity.72 
 
1.2.1.3. Nucleophilic 18F-Substitution Reactions 
Some of the most important 18F nucleoside PET radiotracers such as [18F]FLT ([18F]-3’-
fluoro-3’-deoxythymidine, 15)73, [18F]FMAU ([18F]-2’-fluoro-5-methyl-1-beta-D-
arabinofuranosyl uracil, 20)74 and [18F]FUdR ([18F]-2’-fluoro-2’-deoxyuridine, 22)75 are 
routinely synthesized using nucleophilic 18F-fluorination reactions. A selection of the 
most well-studied and utilized 18F-labeled nucleoside tracers is shown in Figure 1.10. 
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Figure 1.10: A selection of important 18F-labeled nucleoside PET radiotracers including 
[18F]FLT ([18F]-3’-fluoro-3’-deoxythymidine, 15), [18F]FMAU ([18F]-2’-fluoro-5-
methyl-1-beta-D-arabinofuranosyl uracil, 20), [18F]FAU ([18F]-2’-fluoro-1-beta-D-
arabinofuranosyl uracil, 21) and [18F]FUdR ([18F]-2’-fluoro-2’-deoxyuridine, 22). 
 
The nucleophilic 18F- is commonly produced by the nuclear reaction 18O(p,n)18F from 
enriched [18O]H2O as mentioned in section 1.1.2.1.2. The radioactive fluoride, 18F- from 
the target is then trapped on an ion exchange column which allows the recovery of 
[18O]H2O. The trapped 18F- is then eluted from the ion-exchange resin using potassium 
carbonate in a water/acetonitrile solution. However, the aqueous fluoride obtained is a 
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poor nucleophile because of its high degree of solvation. The subsequent addition of the 
phase-transfer reagent kryptofix-222 (K222), followed by the removal of water through 
azeotropic evaporation with anhydrous acetonitrile has proven to be a crucial step in 
improving the nucleophilic reactivity of the [18F]fluoride ion for nucleophilic 
substitution reactions. The azacryptand K222 forms a strong complex with the potassium 
cation as depicted in Figure 1.11 and leaves the fluoride ion exposed and more 
nucleophilic when dissolved in a polar non-protic solvent such as DMF, DMSO, or 
acetonitrile. 
	  
Figure 1.11: Complexation of the potassium ion (K+) by the azacryptand kryptofix-222 
isolating the radiolabeled fluoride ion (18F-). 
 
In addition to [18F]fluoride activation, the reacting precursor molecule is required to 
have a suitable leaving group. Direct 18F nucleophilic labeling can be subdivided into 
two categories: aliphatic 18F labeling and aromatic 18F labeling strategies.67 
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1.2.1.3.1. Aromatic 18F Nucleophilic Reactions 
In comparison to the widely encountered electrophilic aromatic substitutions, direct 
nucleophilic aromatic substitution (SNAr) reactions that are mainly used to generate 18F-
labeled aromatic compounds are inherently difficult reactions. This effect is due to the 
electrostatic repulsion between the electron-rich domain of most aromatic rings and an 
electron-rich/negatively-charged nucleophile (e.g. fluoride). Thus the aromatic rings are 
suitably activated by strong electron-withdrawing groups (e.g. nitro, cyano or acyl) on 
the ortho and/or para positions relative to the leaving group (Scheme 1.2). Common 
leaving groups used in nucleophilic aromatic 18F-fluorination reactions include nitro, 
trialkylamine, halogen, mesylate, tosylate, triflate or iodinium salts. Harsh reaction 
conditions such as temperature ranging from 120 to 160 oC and reaction solvents, 
DMSO or DMF are employed for this type of reaction.76 
	  
Scheme 1.2: Aromatic nucleophilic substitution of a leaving group facilitated by 
[18F]Fluoride in the presence of EWGs on the aromatic ring.76  
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In recent years, the use of diaryl iodinium salts as precursors in nucleophilic aromatic 
18F-substitution reactions has emerged extremely useful for the synthesis of a range of 
simple [18F]fluoroaromatic compounds in good radiochemical yields (RCY) and in short 
reaction times. An example is given in Scheme 1.3, which depicts the synthesis of 1-
bromo-4-[18F]fluorobenzene, 23.77 
	  
Scheme 1.3: Synthesis of 23 from bis(4-bromophenyl)iodonium salts. 
	  
1.2.1.3.2. Aliphatic 18F Nucleophilic Substitution Reactions 
For the introduction of 18F into a range of molecules, especially nucleosides, direct 
aliphatic nucleophilic substitution reactions are generally used. The only requirement for 
aliphatic 18F nucleophilic substitutions is a good leaving group, such as a triflate, 
tosylate, mesylate or nosylate. However, there is a need to protect any potentially 
competing sites of nucleophilic attack in the molecule (principally alcohol or amine 
groups). Hence, additional synthesis and purification steps are required resulting in 
longer synthesis times. The substrates react according to a pattern of typical SN2 
substitution reactions. Alternatively, certain constrained cyclic systems can be opened 
efficiently with [18F]fluoride ion, for example, in the synthesis of the dimethoxytrityl 
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(DMTr) protected 18F-labeled nucleoside, [18F]5’-O-DMTrFLT, 25 from 5’-O-DMTr-
2,3’-anhydrothymidine, 24 as shown in Scheme 1.4. 
	  
Scheme 1.4: [18F]FLT synthesis from the ring opening of 5’-O-DMTr-2,3’-
anhydrothymidine, 24 by  [18F]fluoride and deprotection of 5’-O-DMTr protected FLT, 
25.79 
Aliphatic nucleophilic substitution reactions with [18F]-fluoride ion are usually 
performed in a polar aprotic solvent such as acetonitrile, dimethylformamide (DMF), 
tetrahydrofuran (THF), dimethylsulfoxide (DMSO) etc. Amongst these solvents, 
acetonitrile is highly preferred as it can be easily removed in vacuo. Generally, protic 
solvents such as alcohols are not used for nucleophilic substitution reactions because of 
their ability to solvate the nucleophile, [18F]fluoride and hence retarding its 
reactivity.78,79  
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1.2.2. Some new methods for Chemistry with [18F]Fluoride ion 
 
1.2.2.1. Enzyme-Catalyzed [18F]Fluorination 
The fact that enzyme-catalyzed chemical transformations produce organic or bioorganic 
molecules in a stereo-, regio-, and chemo-selective manner and that enzymes operate at 
physiological temperature in aqueous solution have been beneficial for application to the 
synthesis of 18F-labeled tracers.80 The first example of the formation of a C-F bond by 
an enzyme called fluorinase, which was isolated from the bacterium, Streptomyces 
cattleya, was reported by O’Hagan and co-workers.81 Initial reports using the fluorinase 
enzyme for radiofluorinations gave low RCYs of about 1%. Subsequently, recent 
studies of 18F-labeling using the over-expressed fluorinase enzyme for the synthesis of 
[18F]-5’-fluoro-5’-deoxyadenine ([18F]5’-FDA, 26) brought about major improvements 
with 95% of radiochemical yield (RCY) in two hours (Scheme 1.5). However, the 
radiofluorination reaction was found to be in equilibrium. In order to give a good RCY, 
this equilibrium was to be shifted towards the synthesis of 26 by introducing a second 
enzyme, L-amino acid oxidase, which removes the L-methionine from the reaction. 
Hence, the equilibrium is shifted towards the right and thereby improving both the rate 
of reaction and overall enzyme expression. Such enzymatic methods for preparing 
radiolabeled compounds are particularly enticing, because of the high chemospecificity 
of enzymes and the simple purification methods utilized to remove the side products.82 
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Scheme 1.5: The coupled fluorinase-oxidase enzymatic reaction for the synthesis of 
[18F]-5’-fluoro-5’-deoxyadenine, ([18F]5’-FDA, 26).82 
 
1.2.2.2. Microwave Enhancement of 18F Incorporation 
The use of microwaves to enhance radiochemistry has been gaining popularity as it 
offers speed, selectivity and efficiency of reactions. Upon the availability of controlled 
and user-friendly commercial microwave systems, earlier concerns on the safety 
regarding pressure and temperature controls have been addressed. Currently, some 
instruments also provide visual monitoring of the reaction. In comparison to 
conventional heating modes, the reaction times can be remarkably reduced from hours 
to minutes and seconds by adopting the microwave technology, which is ideally suited 
to the chemistry of 18F incorporation, given the time constraints imposed by the half-life 
of 18F isotope (110 min). Decreases in reaction time and in the amount of required 
precursors, and improved radiochemical yields (RCY) have proved to be of greater 
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advantage in the multi-step syntheses of radiotracer molecules. The decreased amount of 
precursor not only saves precious starting materials, but also reduces the product 
purification steps.83-86 Examples of [18F]- radiolabeling reactions under microwave 
conditions are shown in Scheme 1.6.87-88 
	  
Scheme 1.6: Examples of microwave-enhanced nucleophilic substitutions used in the 
syntheses of 18F-labeled tracers. In reaction 1, the microwave-assisted [18F]-
radiolabeling by bromine substitution resulted in better yields of 80-85% compared to 
the conventional thermal reaction (15-25%). In reaction 2, the microwave-assisted tosyl 
substitution by the [18F]fluoro group, which is the first step for the radiosynthesis of the 
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radiotracer, 9-(4-[18F]fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG) gave better 
yields (30-40%) than the corresponding procedure with conventional heating (4-5%). 
  
1.3. Main Aims and Objectives  
The ability to monitor tumour progression and treatment response in cancer patients 
using the currently most frequently used PET imaging technique, has become a 
significant objective of modern cancer diagnosis and treatment. Although 3’-[18F]fluoro-
3’-deoxythymidine ([18F]FLT) is one of the most important clinical PET biomarkers, the 
current methods for the radiosynthesis of [18F]FLT have been facing obstacles such as 
low overall yields and time-consuming synthesis. 
Thus, one of the main aims of this project was the development of a new efficient 
radiochemical synthetic route to the tracer molecule, [18F]FLT. Initial studies for FLT 
synthesis were focused on the non-radioactive 19F isomer by varying and optimizing 
conditions for the incorporation of different protecting groups and also fluoridation 
reactions. The introduction of fluorine into the synthesized precursor molecules by 
nucleophilic displacement reaction was to be carried out using both conventional 
thermal methods and microwave-assisted techniques. Afterwards, the feasible reaction 
conditions were to be applied for the radiosynthesis of [18F]fluorine labeled FLT. 
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Another objective was to implement optimization studies on the fluoridation step and 
the synthesis of [18F]FLT Pronucleotide phosphoramidates ([18F]FLT ProTides) as a 
new class of diagnostic PET imaging agents using conventional thermal methods, which 
can be applied later on for the radioactive [18F] labeling studies of [18F]FLT ProTide 
molecules. 
The synthesis of a series of 19F-FLT based ProTide analogues and their biological in 
vitro evaluation in various human cell lines as potential new therapeutic agents that can 
efficiently cross cell membranes and exhibit minimal toxicity than the parent nucleoside 
FLT, was also one of the major goals of this project. 
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2. Synthetic routes to 19F-FLT 
 
2.1. Brief rationale 
One of the main purposes of this project included the development and optimization of a 
fast and efficient chemical synthetic route to 19F- FLT, which can be adapted to the 
radioactive production of the clinically used tumour proliferation biomarker 3’-[18F]-
fluoro-3’deoxythymidine, [18F]-FLT. Fortunately, the synthetic chemistry of the 
positron emitting isomer, 18F mirrors that of the non-radioactive natural isomer, 19F. 
Therefore, the establishment and optimization of reaction conditions can be carried out 
under conventional thermal conditions without the need for radiochemical facilities, 
with final transfer of the optimal synthetic route and purification conditions to the 
radiochemical facility of Cardiff University, Wales Research and Diagnostic Positron 
Emission Tomography Imaging Centre (PETIC) at the University hospital. 
This chapter has mainly two different approaches for synthesizing 19F-FLT: 
1. Use of different nucleophilic fluorides using various protecting group 
strategies and reaction conditions, in which work was designed to lay the 
framework for translation of [18F]fluoride radiochemistry to [18F]FLT. 
2. Use of electrophilic fluorinating agents such as DAST 
(diethylaminosulphur trifluoride) or XTalFluor reagents to generate FLT 
in sufficient quantities for ProTide studies. 
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2.2. 19F- FLT synthesis for [18F]fluoride radiochemistry studies 
 
2.2.1. FLT synthesis via Mitsunobu reaction with 5’-O-protection 
Since the furanosyl moiety of the thymidine nucleoside consists of both primary and 
secondary hydroxyl groups at its 5’ and 3’ positions respectively, the primary hydroxyl 
functionality had to be protected with a suitable protecting group that allows the 
regioselective halogenation at the 3’ position. In order to carry out a successful reaction, 
it was essential that the appropriate protecting group met certain conditions such as  
 i.   simple and straightforward process of protection  
             ii.  stability to reaction conditions 
             iii. easy and fast removal ensuring a good yield of the expected product. 
 
A generic representation of the synthetic route to FLT involving protection and 
deprotection of the hydroxyl group at the 5’- position of the thymidine nucleoside, 1 is 
shown in Scheme 2.1. The route consists of four major steps: 
(a)  protection of the 5’-hydroxyl group of thymidine  
(b) creation of a more electrophilic centre at the 3’-nucleoside position by the 
formation of a six-membered 2,3’-anhydro ring through Mitsunobu reaction 
(c1) nucleophilic fluoridation reaction at the 3’ position after formation of the   
anhydro ring or 
(c2) direct nucleophilic substitution of the 3’ hydroxyl group and 
(d) deprotection of 5’-hydroxyl  group to generate FLT, 10.  
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Scheme 2.1: Generic route for the synthesis of FLT, 10 involving 5’-O-protection of the 
thymidine nucleoside 1, nucleophilic displacement by fluorine and deprotection of the 
protecting group (PG). 
 
Various types of protecting groups for the protection of the 5’-hydroxyl group were 
studied, namely the p-methoxybenzoyl (PMBz) group, the dimethoxytriphenylmethyl 
(DMTr) group and the triphenylmethyl (Tr) group, which are common protecting groups 
for 5’-hydroxyl groups of nucleosides and their analogues.  
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The mechanism of the Mitsunobu reaction, which allows the intramolecular conversion 
of the secondary alcohol group present at the 3’-position of thymidine into a six-
membered 2,3’-anhydro cycle, is shown in Scheme 2.2. The triphenyl phosphine, 27 
combines with diisopropyl azodicarboxylate (DIAD), 28 to generate a zwitterionic 
phosphonium intermediate, 29. Subsequently, the intermediate deprotonates the 3’-
secondary alcohol group on thymidine to form the anionic nucleophile, 30. This 
nucleophile binds to the phosphonium ion and the resulting nucleophile performs an SN2 
attack to yield the final substitution product 5’-O-protected-2,3’-anhydrothymidine, 31 
with an inverted stereochemistry at C-3’. The formation of a strong P=O bond in the by-
product triphenylphosphine oxide, 32 helps to drive the reaction forward.1, 2 
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2.2.1.1. Protecting group: p-methoxybenzoyl (PMBz) 
 With reference to previous studies carried out for uridine analogues, the PMBz group 
was employed for the protection of the primary hydroxyl group.3 An electrophilic, 2,3’-
anhydro cyclic intermediate was generated under Mitsunobu conditions (Scheme 2.3), 
which later on served as an effective precursor for the fluoridation reaction. 
 
Scheme 2.3: Mitsunobu reaction performing both 5’-O-PMBz protection and 
intramolecular cyclization on thymidine 1. 
The synthesis of 5’-O-p-methoxybenzoyl-2,3’-anhydrothymidine, 33 from thymidine, 1 
comprised of a one-pot reaction, which involved p-methoxybenzoic acid, triphenyl-
phosphine, DIAD and DMF solvent. Hence both the PMBz protection reaction of the 5’-
OH group and the formation of the 2,3’-anhydro ring were performed together. The 
reagent DIAD was added in two portions; first at the start of the reaction and the second 
after 1.5 hours maintaining the temperature at 00 C. Upon the second addition, the 
desired compound started to form and was filtered out to obtain white powder of the 
product in 93% yield after washing with brine and ether. It is noteworthy that the 
reaction proceeded with a stereogenic inversion at the 3’ position forming an anhydro 
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bond between the 3’-position of furanosyl unit and 2-position of the thymine as 
illustrated in Scheme 2.3. The formation of the protected 2,3’-anhydro thymidine was 
confirmed by analyzing its exact mass using NMR spectroscopy and mass spectrometry. 
The next step was to fluoridate the 3’-position of the 2,3’-anhydrothymidine formed 
after PMBz protection, which was successful using cesium fluoride (CsF) in DMF 
solvent followed by stereogenic inversion at the 3’-position. It is observed that the rate 
of the nucleophilic fluoridation reaction is higher and faster through the formation of the 
2,3’- anhydro ring since the resulting 6-membered arrangement is in a 
thermodynamically strained state and hence more susceptible than the non-cyclic 
counterpart towards nucleophilic attack as shown in Scheme 2.4. 
 
Scheme 2.4: SN2 mechanism of 3’-fluoridation reaction.  
 Although the fluoridation reaction was carried out for 24 hours at 120 oC, the reaction 
yielded 91% of the pure compound merely by filtering the reaction precipitate and 
washing it with ether.  
Other fluoridating reagents and conditions were also tested as shown in Table 2.1. 
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Table 2.1: Fluoridation reactions of 5’-O-PMBz-2,3’-anhydrothymidine, 33. 
F- source solvent reaction time (h) yield 
CsF DMF 24 91% 
KF DMF 24 / 
TBAF DMF 12-24 / 
 
In consideration of the half-life of 18F (t1/2 = 110 min), a reduced fluoridation reaction 
time was essential. The use of potassium fluoride (KF) and (tetra-N-butylammonium 
fluoride) TBAF as fluoridating agents was not successful as the starting material was 
retained completely with no progress in reaction. Hence microwave promoted 
fluoridation studies of 5’-O-PMBz-protected thymidine, 33 were carried out as shown in 
Table 2.2: Microwave promoted reactions. 
Reaction 
mixture 
result time yield (%)  
decomposed 
product 
1 hour / 
pure product after 
filtration 
30 min 60  
33 (1 mmol), CsF 
(3.138 mmol), 
DMF (3.5 mL) 
minor impurities  15 min 80  
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Microwave experiments were performed in the Department of Chemistry, Cardiff 
University in the laboratory of Dr. Mark Bagley. For all the three microwave 
experiments, the compound 33 (0.36g, 1 mmol) and CsF (0.48g, 3.138 mmol) were 
dissolved in anhydrous DMF (3.5 mL), stirred and sonicated to form a homogeneous 
solution mixture. The sealed vessel containing the reaction mixture was then placed in 
the microwave and irradiated at 120 oC with a power of 150 W and pressure of 100 psi 
at varying reaction times as shown in Table 2.2. However, the microwave reaction 
which lasted 1 hour led to the decomposition, as the resulting solid compound was 
black. The reactions which lasted 30 and 15 minutes were able to generate the desired 
compound, 34 with yields of 60% and 80% respectively. 
The final step was to remove the PMBz protecting group from the 5’-O-position of 3’-
fluorothymidine using sodium methoxide in methanol. However, the deprotection 
reaction was not successful as peaks of the aromatic protons of PMBz-group were still 
detected on the 1H-NMR spectrum even after purification by preparative column 
chromatography.  
Hence the DMTr protecting group was used afterwards. 
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2.2.1.2. Protecting group: 4,4’-dimethoxytriphenylmethyl (DMTr) 
As suggested from the literature, the dimethoxytrityl group was used to protect the 5’-
hydroxyl group of thymidine, since it was more reliable in terms of simple and fast 
deprotection conditions.4,5 This protecting group can also impart crystallinity to many 
low-melting solids.6 However, the conditions used for the protection and purification of 
the resulting 5’-O-DMTr-thymidine were more time-consuming compared to the PMBz- 
group.  
The dimethoxytrityl group was preferred over the trityl moiety since it is more acid 
sensitive and removed more rapidly at lower temperature.7 The protection was carried 
out using dimethoxytrityl chloride and anhydrous pyridine at room temperature as 
depicted in Scheme 2.5. Although the reaction time was only three hours, the 
purification of the desired compound was time consuming. The purified DMTr- 
protected thymidine, 35 was isolated by preparative column chromatography with 59 % 
yield. The structure of the compound was confirmed by NMR spectroscopic and mass 
spectrometric analysis. 
 
2.2.1.2.1. Fluoridation without a precursor  
Initially, it was thought to attempt the fluoridation reaction by the direct replacement of 
the hydroxyl group on the 5’-O-DMTr protected thymidine, 35 by treating it with a 
suitable fluoride such as CsF as represented in Scheme 2.5. Direct replacement of the 
OH-group at the 3’-position of 35 by a fluoride emerged to be a highly challenging task 
as the nucleophilic substitution of the hydroxyl group upon fluoride attack is less 
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favourable compared to leaving groups such as mesyl or tosyl. This is mainly because 
the hydroxyl group is a poor leaving group.  Also the reaction was expected to be very 
slow and low-yielding. An authentic sample of FLT was purchased from the supplier 
Carbosynth as reference and an NMR spectrum of the reference FLT in d4-MeOD was 
obtained to assess the viability of fluoridation studies. It is thought that if the 5’-O-
DMTr protected thymidine is converted into a 2,3’-anhydro complex, the rate of the 
fluoridation reaction could be enhanced. Several solvents such as DMF and DMSO were 
tested to identify the most efficient reaction medium. It was found that when acetonitrile 
and methanol are combined in a 1:1 ratio, fluoridation emerged to be more favourable. 
The formation of 5’-O-DMTr-3’-fluorothymidine, 36 was confirmed by NMR 
spectroscopy followed by stereogenic inversion at the 3’ position and the attack of the 
fluoride nucleophile (F-) occurred from the β-face of the nucleoside. At this point, it was 
confirmed that the fluoridation reaction would result in the stereogenic inversion of the 
configuration of the stereocenter as it is a typical nucleophilic SN2 reaction (substitution 
reaction, 2nd order). But for the stereoselective synthesis of FLT, it was necessary for the 
fluoride nucleophile to attack from the α-face of the nucleoside. Therefore, a stronger β-
configured electrophile had to be introduced at the 3’-position of the 5’-O-protected 
thymidine for the fluoride to attack from the α-face in an SN2 nucleophilic manner. 
The removal of this particular protecting group was found to be more advantageous than 
the previous group used for the protection of 5’- hydroxyl functionality as this involved 
simple drop-wise addition of aqueous 1N HCl over 5 minutes and raising the 
temperature to 50 0C. The dimethoxy trityl group was released as a cation with a 
characteristic bright red-orange colour. The white precipitate that resulted from the 
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reaction showed no peaks for the DMTr protons in its 1H-NMR spectrum, confirming 
the complete deprotection of the DMTr group from the 5’-O-position of the nucleoside. 
But unfortunately, the peaks did not correspond to the original structure of the expected 
product, FLT due to decomposition.   
 
Scheme 2.5: Fluoridation of 5’-O-DMTr-thymidine, 35.  
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2.2.1.2.2. Fluoridation following precursor formation 
In order to improve the rate of the fluoridation reaction and conduct stereoselective FLT 
synthesis, the analogy of using the precursor 2,3’-anhydro derivative of the 5’-O-DMTr 
protected thymidine was applied based on the same principle carried out previously for 
the PMBz-protected thymidine.  
Again with the main intention of generating an electrophilic center at the 3’- nucleoside 
position, the 5’-O-(4,4’-dimethoxytrityl)-2,3’-anhydrothymidine, 37 was prepared using 
Mitsunobu reaction conditions.8 The solvent used for this particular reaction was ethyl 
acetate. The dropwise addition of DIAD (1.5eq) into the reaction mixture was carried 
out at 0 0C, and a better yield of the expected product was obtained when the 
temperature at which the addition took place was kept between 0-2 0C. Once all the 
DIAD addition was completed, the reaction was continued for three hours at room 
temperature. 
From the TLC analysis, it was evident that the product appeared at a different Rf value, 
0.1 (EtOAc-MeOH, 9:1 v/v) compared with the starting material 5’-O-DMTr-thymidine 
appearing at 0.7. Thus preparative column purification enabled a good isolation of the 
white amorphous product with 70% yield.  
Subsequently, it was decided to test this precursor anhydro molecule with various 
fluorides in different polar aprotic solvents as shown in Scheme 2.6. As mentioned 
previously, these types of solvents were preferred to render the nucleophilic 
characteristics of the respective fluoride used.  
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Scheme 2.6: Formation and nucleophilic fluoridation of 5’-O-DMTr-2,3’-
anhydrothymidine, 37. 
 
In the following Table 2.3, a summary of the different reaction conditions that were 
examined is given below using the fluorides, CsF and TBAF.3H2O (Tetra-N-
butylammonium fluoride).  
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 Table 2.3: Fluoridation reactions of 5’-O-DMTr-2,3’-anhydrothymidine, 37. 
Reaction Starting 
material 
(300mg) 
Fluoride 
source  
(3eq) 
Solvent 
(anhydrous) 
(4ml) 
Progress Time 
(hr) 
Temp. 
( 0C) 
1. CsF X 12 160 
2. 
 
DMSO X 1/2 170 
3. 
Compound 
37  
TBAF.3H2O DMF Formed a 
different 
analogue 
(dehydro) 
5 150 
 X= expected product not formed, starting material remaining. 
 
The first reaction was an overnight experiment, in which CsF was the nucleophilic 
fluoride and DMSO was the solvent, since only starting material could be detected by 
TLC analysis (DCM:MeOH, 9.6:0.4 v/v) carried out at intervals of 2 hours. After 
collecting a cream precipitate by pouring into excess water, 1H and 19F- NMR studies 
were done and revealed that the expected product, 38 was not formed since the peaks in 
the spectra corresponded to that of the starting material. The DMSO used here was 
purchased as anhydrous (was a fresh bottle used). However given the notorious 
hygroscopic nature of DMSO, it is possible that small traces of water might have 
compromised the nucleophilicity of fluoride anion in this reaction, leading to return of 
unreacted starting material. 
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While conducting the second reaction, where tetra-n-butylammonium fluoride trihydrate 
(TBAF.3H2O) and the same solvent were utilized, TLC analysis after 30 minutes 
showed the appearance of a new spot (Rf =0.43, DCM-MeOH 9.6:0.4 v/v) different to 
that of starting material (Rf = 0.1). Hence the reaction was stopped and preparative 
column purification was done to isolate the newly formed molecule. Although the same 
reaction conditions were employed in a recently published journal by S.K. Nandy and 
M.G.R Rajan9 for the introduction of the radioactive fluoride to synthesize [18F]-FLT, 
these conditions proved to be unsuccessful for the thermal fluoridation reaction as no 
peak was detected in the 19F- NMR and hence indicating the absence of fluorine at the 
expected 3’ nucleoside position. In the 1H-NMR, the H2’ peaks were absent and hence it 
is suspected that another unknown analogue might have formed. 
 
For the final reaction, where the 5’-O-DMTr-protected anhydro precursor, 37 was 
heated to 150 0C under reflux with the same fluoride, TBAF.3H2O and a different 
anhydrous solvent, DMF, TLC analysis after one hour showed a new spot at Rf = 0.25 
(DCM:MeOH, 9.6:0.4 v/v). The reaction was quenched after 5 hours by pouring the 
reaction mixture into excess water and thereby forming a white precipitate, which was 
collected by filtration. The white amorphous crude product (61%) was purified by 
column chromatography to isolate the unknown product as a white amorphous powder 
(40%) and was subjected to NMR analysis. But in 1H-NMR, both the H2’ and H3’ were 
found to be absent. It is suspected that the TBAF trihydrate, being a strong base, is 
attacking at the H2’ as shown in Scheme 2.7 to form a double bond between C2’ and C3’ 
and thereby opening the six-membered anhydro ring. This same mechanism was seen in 
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the Tetrahedron paper by P. Langen et al.10 where they used the same reaction 
conditions to obtain 3’-deoxy-2’,3’-didehydrothymidine.  Here in this case, NMR 
results confirmed that it had gone through the same mechanistic pathway and formed the 
didehydro analogue, 39 as TBAF, a trihydrate, contains water which will reduce the 
nucleophilicity of fluoride anion, leading to either no reaction or elimination reaction.  
 
 
Scheme 2.7: Elimination reaction by the fluoride ion to form 5’-O-DMTr-3’-deoxy-
2’,3’-didehydrothymidine, 39. 
As the above reactions failed to obtain the desired product, 5’-O-DMTr-3’-fluoro-3’-
deoxy-thymidine 38, other reaction conditions were tested with the same fluorides in 
acetonitrile and pyridine as solvents. But unfortunately, the use of anhydro precursor 
molecule was rather unsuccessful as these all resulted in the unwanted elimination 
product, 39. Hence more favourable reaction conditions were examined for the 
incorporation of fluoride at the 3’ nucleoside position. 
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2.2.1.2.3.  Deprotection of DMTr- group 
The final step consists of the acid- catalysed removal of the dimethoxytriphenylmethyl 
group at the 5’-O-position of 39 by treating it with a suitable acid such as HCl in 
solvents such as methanol or acetonitrile. 
Although the same deprotecting conditions that were used previously for the DMTr 
removal (Scheme 2.5), were employed this time as well for deprotection of 39, there 
were no identifiable products from proton NMR.  
 
2.2.1.3. Protecting group: Trityl (Tr) 
While carrying out column chromatography purifications of DMTr protected 
compounds, the DMTr group dissociated quite easily despite adding small amounts of 
triethylamine base to the eluent to neutralize the slight acidity of silica. As the 
dimethoxytrityl (DMTr) group is known to be very acid labile, the more stable and 
commercially available protecting group, Trityl was trialled instead. As the use of the 
anhydro precursor was unsuccessful, a different strategy was undertaken where the trityl 
ether of the thymidine nucleoside was first converted into its mesylate analogue, 40 of 
3’-OH and thereby converting it into a good leaving group to enable the formation of the 
lyxo configurated 5’-O-trityl thymidine, 41 through a base mediated reflux reaction, 
followed by a stereogenic inversion of configuration as illustrated in Scheme 2.8. 
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The transformation of the sterically least hindered hydroxyl group (5’-OH) of 
thymidine, 1 into its trityl ether was achieved selectively under the presence of trityl 
chloride and pyridine, which acts as both base and solvent, along with a catalytic 
amount of 4-DMAP. The reaction was carried out for 8 hours under anhydrous 
conditions and heated at 80 0C. Both the tritylation at 5’-OH and mesylation at 3’-OH 
groups of thymidine were performed as a one-pot reaction; maintaining the same solvent 
pyridine, the reaction mixture after tritylation reaction was cooled down to 0 0C and 
mesyl chloride was added drop wise and stirred for one hour. 11 Aqueous work-up was 
required after the reaction was complete and the product, 40 was obtained in 73 % yield 
after column purification. The trityl protected mesylate analogue of thymidine was then 
subjected to a hydroxylation reaction with sodium hydroxide (10 eq) as the 
hydroxylating agent and ethanol as the solvent. The nucleophilic substitution of the 
hydroxide resulted in the stereogenic inversion of configuration at the 3’ position of the 
nucleoside generating the product, 41 with an 85 % yield after silica gel column 
chromatography purification. 
This particular synthetic approach was aimed to be implemented for 18F-FLT synthesis 
as a rapid fluoridation reaction was required considering the half-life of 18F.  
Since the conversion of 5’-O-protected and unprotected 2,3’-anhydrothymidine into the 
3’-fluoro-3’deoxythymidine analogue was unfavourable as mentioned previously, a 
different precursor molecule with a better leaving group was sought for the attack of 
nucleophilic fluoride.  
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The use of nosyl group as a good leaving group is well established in literature. Hence 
the idea was to convert 41 into a 4-nitrobenzene sulfonyl substituted nosyl analogue 42 
that would spontaneously react with the nucleophilic fluoride as presented in the 
Scheme 2.8.  
Nosylation was carried out in the presence of a halide-abstracting reagent, silver triflate 
(AgOTf) that could drive the reaction faster and in the presence of the base, pyridine.12 
The nosyl precursor 42 was obtained in 60% as a yellow solid after column purification. 
This was then subjected to various fluoridation reactions with different nucleophilic 
fluoride sources. The treatment of 42 with three equivalents of tetrabutyl ammonium 
fluoride trihydrate (TBAF.3H2O) gave the desired fluorinated intermediate 43 (25%) 
after 30 minutes of heating under reflux with DMF as the solvent along with Kryptofix 
[222] to enhance the nucleophilicity of fluoride and drive the reaction forward.  
 
 
72	  
	  
 
 
 
Scheme 2.8: Synthesis of FLT, 10 via the nosyl precursor 42. 
The acid sensitive trityl group was removed by heating compound 43 with 80% acetic 
acid under reflux condition for half an hour. FLT, 10 was generated after column 
purification with a yield of 50%.  
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2.2.2. FLT synthesis without 5’-O- protection 
With the main intention of reducing the number of synthetic steps by excluding the 
protecting group on the 5’-position of thymidine and hence eliminating the protection 
and deprotection steps, the idea of generating FLT was attempted from just two steps, 
i.e. 
1. intramolecular cyclization 
2. nucleophilic fluoridation reaction. 
As shown in Scheme 2.9, the unprotected thymidine was converted into 2,3’-
anhydrothymidine, 44 using Mitsunobu reaction conditions to accomplish 
intramolecular cyclization for creating an electrophilic center at the 3’-position. The 
reaction was carried out using different solvents such as DMF and acetonitrile. It was 
found that upon using acetonitrile as the solvent, a better yield of 18% was obtained 
than using DMF which resulted in only 10% yield of 44. Also when drop-wise addition 
of DIAD was performed at a temperature range of -15 to -5 0C and the reaction was 
allowed to run at 0 0C, a higher yield of the desired product (30%) was observed than 
when running the reaction at room temperature (18%) with acetonitrile as the solvent.13 
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Scheme 2.9: Formation and fluoridation of the unprotected 2,3’-anhydrothymidine, 44.  
The purification of the compound 44 consisted of its precipitation in ethyl acetate and 
collection by filtration. Further purification was done by column chromatography using 
DCM-MeOH as the eluent in 8:2 v/v ratio to isolate the desired precursor molecule as a 
white amorphous powder in 57% yield with Rf =0.3.   
The next and final step was to treat the 2,3’-anhydrothymidine precursor, 44 with a 
suitable nucleophilic fluorinating reagent to allow fluoridation. Hence, it was tested 
against different nucleophilic fluorides such as CsF, TBAF.3H2O and KF. A summary 
of the various reaction conditions used for different fluorides is shown in the Table 2.4. 
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Table 2.4: A summary of fluoridation reactions with 2,3’-Anhydrothymidine, 44. 
Expt. Starting 
material 
(200mg) 
Fluoride 
source  (3eq) 
Solvent 
(anhydrous) 
(2ml) 
Time (hr) Temp. 
( 0C) 
1.  
DMSO 
 
1 
 
120 
2.  
DMF 
 
1 
 
100 
3. 
 
 
CsF 
 
PYRIDINE 
 
2 
 
100 
4.  
DMSO 
 
2 
 
120 
5. 
 
 
TBAF.3H2O  
DMF 
 
1.5 
 
150 
6.  
KF 
 
DMF 
 
6 
 
100 
7. 
 
 
 
 
 
 
  Compound 
44 
KF + 
Kryptofix 
[222] 
 
DMF 
 
0.5 
 
80 
 
At first, compound 44 was heated with CsF and pyridine to about 120 0C under N2 
atmosphere and reflux for two hours. After TLC analysis, it was observed that a new 
spot appeared at Rf = 0.5 which was different to that of 44 (Rf=0.1) in DCM-MeOH 
(9.5:0.5 v/v). Thus column chromatographic purification enabled the isolation of the 
crude compound as a white amorphous powder in 58% yield. A clear NMR spectrum 
was generated representing successful purification with no other impurities present. It 
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was concluded that the same unwanted elimination reaction had occurred as with 
previously mentioned 5’-O-DMTr-2,3’-anhydrothymidine, 37 to form 3’-Deoxy-2’,3’-
didehydrothymidine, 45 as shown in Scheme 2.10.  
The treatment of 44 with TBAF.3H2O and DMF solvent provided the same 
disappointing results as different side reactions occurred, which were obvious from TLC 
analysis after 90 minutes. Considering the importance of the azacryptand Kryptofix 
[222] in radiochemistry to improve the nucleophilicity of the [18F]fluoride ion as 
mentioned in Chapter 1, K222 was used along with KF in one of the reactions to increase 
the nucleophilicity of the fluoride ion. But a progress in reaction could not be observed. 
The spots proved very difficult to separate even after column chromatographic 
purification. As all the resulting products from the different fluoridation reactions were 
analyzed, it was confirmed that the desired product was not formed. 
 
Scheme 2.10: Schematic representation of the didehydro thymidine analogue formation. 
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2.3. 19F- FLT synthesis for ProTide studies 
	  
For the purpose of ProTide studies as detailed in Chapter 4, it was necessary to generate 
FLT in larger quantities of minimum 5 g. Even though FLT was commercially available, 
it was a very expensive nucleoside to be purchased on a large scale. 
The direct replacement of oxygen by fluoride in organic molecules is commonly 
referred to as deoxofluorination and was implemented in this case, using electrophilic 
fluorinating reagents. DAST and Deoxo-Fluoro (Figure 2.1) are the most widely used 
deoxofluorinating reagents. But these reagents were extremely thermally unstable and 
highly explosive in nature. DAST degraded more rapidly with somewhat larger heat 
evolution. These are also liquids that discolour with aging and require redistillation, 
hence the decomposition can easily be observed.14 However, DAST was used in this 
case for the selective deoxofluorination of compound 41 at 3’ position. But when 0.1 g 
of compound 41 was used for the reaction, only 50% of the required product 43 was 
obtained and when used on a large scale, the selectivity was driven towards side product 
formation resulting in no product. 
 
Figure 2.1: Structures of popular deoxo-fluorinating reagents 
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In the quest for safe and stable deoxofluorinating reagents capable of incorporating 
fluorine in a controlled fashion, dialkylamino difluorosulfinium (XTal Fluor-E) and 
morpholinodifluorosulfinium tetrafluorobarate (XTal Fluor-M) salts were found to act 
as surrogates for aminosulfur trifluorides and they emerged to be safer and more 
efficient alternative reagents. When used in conjunction with exogenous fluoride source 
or promoters such as Et3N.3HF, Et3N.2HF, or DBU, these reagents were able to 
effectively convert alcohols to alkyl fluorides; thereby leading to fewer elimination 
byproducts as compared to DAST.15  
The synthesis of Xtal Fluor reagents (Figure 2.2), were first reported over three decades 
ago by Markovskii et al.16 In recent years, the use of Xtal Fluor-M as a 
deoxofluorinating reagent was reported in literature by Pashinnik et al. for the 
deoxofluorination of an allylic alcohol in acetonitrile to yield the corresponding fluoride 
in 85% as a mixture of epimers.17 Since then various types of alcohols have been 
converted to their respective fluorides with the use of Xtal Fluor deoxofluorinating 
reagents. Xtal Fluor reagents have demonstrated not only enhanced thermal stability 
over DAST, but also improved preparatory methods excluding hazardous distillations 
which otherwise were required for synthesizing DAST. On the contrary to DAST, these 
reagents were more selective in providing less elimination side products and can be 
easily handled as free-flowing solid which do not generate highly toxic and corrosive 
HF.18 
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Figure 2.2: Structures of XTal Fluor reagents. 
 
In this case, the morpholinodifluorosulfinium tetrafluoroborate (XtalFluor-M), which 
was commercially available as a white crystalline salt, was used to perform 
deoxofluorination on compound 41 and yielded 43 with a comparatively better yield of 
75% when used on a large scale starting with 5g of 41 as described in Scheme 2.11. 
Procedures 1 (tritylation and mesylation), 2 (hydroxylation) and 4 (deprotection of Tr 
group) were followed in the same manner as detailed in section 2.2.1.3. A good yield 
(93%) of the desired final product FLT, 10 was obtained after column purification with 
dichloromethane: methanol eluent. The nucleoside product was further used for the 
synthesis of various FLT phosphoramidates. 
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Scheme 2.11: Synthesis of FLT, 10 via deoxofluorination of 41. 
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2.4. Summary 
The synthesis of 19F-FLT, 10 for the [18F]fluoride radiochemistry studies was achieved 
using 5’-O-trityl protected nosyl precursor molecule using TBAF.3H2O as the fluoride 
source. Although, 19F-FLT synthesis was unsuccessful with 5’-O-PMBz and DMTr 
protected precursor molecules consisting of the anhydro ring at the 3’-position as the 
leaving group for the nucleophilic substitution by the fluoride ion, these methods were 
repeated under radiochemical conditions as described in Chapter 3. 
For the purpose of ProTide studies (Chapter 4), 19F-FLT was synthesized in larger 
quantities using the electrophilic reagent, XTalFluor-M. 
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3. Radiosynthetic routes to [18F]-FLT 
and its ProTides 
	  3.1. Radiosynthesis of [18F]-FLT	  
	  
In spite of currently being the most promising and widely used PET tracer molecule for 
monitoring cellular proliferation in tumours, the clinical applicability of [18F]-3’-fluoro-
3’-deoxythymidine ([18F]FLT) has been limited by a number of radiosynthetic 
drawbacks. These include the lengthy synthesis of the precursor molecule, time-
consuming purification techniques such as preparative high performance liquid 
chromatography (HPLC) and low radiochemical yields of the tracer molecule ranging 
from 5-20%.1 Therefore, it was felt that there is an urgent need to overcome these 
limitations. Hence, the first and foremost objective was the development of a fast and 
efficient synthetic route for the radiosynthesis of [18F]FLT at the new Wales PET 
Imaging Centre (PETIC) located at the University Hospital of Wales.  
 
3.1.1. Previous studies 
One of the earliest examples of [18F]FLT radiosynthesis was reported by Grierson et al., 
using a complex precursor molecule, 1-(2-deoxy-3-O-(4-nitrobenzenesulfonyl)-5-O-
(4,4’-dimethoxytrityl)-β-D-lyxofuranosyl)-3-N-(2,4-dimethoxybenzyl) thymine. In this 
method, a solution of [18F]fluoride, potassium carbonate and Kryptofix [2.2.2] was dried 
by azeotropic distillation with acetonitrile under argon at 100 oC as the complete 
absence of atmospheric moisture was required to enhance the nucleophilicity of 
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[18F]fluoride. The solution mixture was then solubilized in anhydrous acetonitrile and 
treated with the nosylate labeling precursor, 46 as shown in the Scheme 3.1 for 10 
minutes. To the resulting residue, ceric ammonium nitrate (CAN) in 4:1:1 
MeCN/EtOH/water was added at 100 oC to remove the 4,4’-dimethoxytrityl (DMTr) 
and 2,4-dimethoxybenzyl protecting groups. Subsequently, the crude mixture was 
filtered and then purified in a semi-preparative C-18 HPLC eluted with 10% EtOH in 
sterile water to yield [18F]FLT, 15 with a radiochemical yield (RCY) of 13% by the 
nucleophilic displacement of 3’-O-nosyl group on the precursor molecule with 
[18F]fluoride. However, many disadvantages have been associated with this particular 
synthetic methodology such as time consuming deprotection steps, excessive [18F]FLT 
degradation to [18F]fluoride by the use of CAN and the formation of precipitating ceric 
salts, which would represent a difficult procedure for an automated synthesis.2 
	  
Scheme 3.1: Synthesis and purification of [18F]FLT described by Grierson and Shields.2 
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Thereafter, many alternative synthetic methodologies have been brought forward using 
different precursor molecules in the nucleophilic [18F]fluoridation reactions to generate 
[18F]FLT, 15. One such notable study was the use of 5’-O-(4,4’-dimethoxytrityl)-2,3’-
anhydrothymidine, 37 by Machulla and coworkers as a precursor for the radiosynthesis 
of [18F]FLT, which is illustrated in Scheme 3.2 to generate 5’-O-DMTr-3’-
[18F]fluorothymidine, 47. The anhydro structure acts as both an electrophilic center at 
the 3’- position and as a pyrimidine protecting group. This led to simplifications 
regarding the precursor synthesis, labeling and purification of [18F]FLT. However the 
synthesis times ranged between 90 min and 140 min.3 It is worth mentioning that the 
introduction of other leaving groups such as methylsulfonyl (mesyl=Ms), p-
toluenesulfonyl (tosyl=Ts) and trifluoromethanesulfonyloxy (triflate=Tf) to create an 
electrophilic center at the 3’-position, have also been recorded in literature. 
Conventionally, the OH-group at the 5’-position of the precursor molecule is protected 
with either of the easily removable triphenylmethyl (Tr) or 4,4’-
dimethoxytriphenylmethyl (DMTr) protecting groups, since the hydroxylic groups are 
thought to decrease the nucleophilicity of [18F]fluoride.4 
	  
Scheme 3.2 : Synthetic method for 18F-FLT developed by Machulla and coworkers.3 
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Organic solvents such as anhydrous DMSO, acetonitrile or DMF are often used as the 
reaction medium. For the nucleophilic fluoridation reaction, phase transfer reagents such 
as kryptofix 222, K2CO3, TBA-HCO3, and CsCO3 are used along with the radioactive 
fluoride ion, 18F- that is produced from the cyclotron, in order to increase the 
nucleophilicity of the fluoride ion and accelerate the rate of [18F]-radiolabeling 
reactions.5 
 
3.1.2. Radiosynthetic routes for [ 18F]FLT using different precursors 
In this study, preliminary work was focussed on optimising existing reaction conditions 
for [18F]FLT synthesis from previously prepared precursor molecules as described in 
chapter 2. The idea was to incorporate the radioactive fluoride that is generated from the 
cyclotron into the previously prepared precursor molecules in an automated process. 
This was carried out in an Eckert and Ziegler Nuclear Interface Module (Modular Lab) 
as shown in Figure 3.1 which was configured for general-purpose fluoridation, 
deprotection and HPLC purification; finally generating the pure PET tracer molecule 
[18F] FLT. All these steps were automated in the modules using developed software 
programs. It was necessary to use an automated radiosynthesis system performed by the 
Modular Lab application software and place these inside a hot cell for radiation safety 
purposes due to the production of radiolabeled compounds with high activities. The hot 
cell is self-shielded and large enough to accommodate the modular lab synthesizer 
providing sufficient shielding against radiation in all directions.  
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Figure 3.1: Modular Lab Synthesizer placed inside a hot cell at PETIC. 
 
Each of the previously prepared precursor molecules were subjected to different reaction 
conditions such as varying temperature, reactant concentration, solvents and reaction 
time in order to achieve the best optimised [18F]FLT synthetic route. A general 
representation of the radiochemical preparation of [18F]FLT, 15 is given in Scheme 3.3 
below. 
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             Scheme 3.3:  General schematic representation of [18F]FLT, 15 synthesis 
 
As the project required further technical knowledge of radiochemical synthetic 
processes using Modular Lab software and module equipments, special training was 
given by Dr. Stephen Paisey prior to carrying out work at PETIC.  
Repeated automated processes were trialled for optimizing reaction conditions such as 
the maximum temperature for solvent evaporation, reaction solvents and also to ensure 
module equipments were performing according to required specifications.  
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3.1.2.1. Module for remote [18F]FLT synthesis 
The [18F]FLT module consisted of nine main components as marked on Figure 3.2:  
(A)  reaction vial 
(B) QMA (quaternary methyl ammonium) anion exchanger cartridge, which was 
preconditioned using 5 mL of 8.4% aqueous NaHCO3 solution followed by 10 
mL of water, in order to trap 18F- from the cyclotron 
(C) Kryptofix [2.2.2] (K222) vial 
(D) anhydrous acetonitrile (CH3CN) vial for the purpose of azeotropic 
evaporation 
(E) precursor vial, which was charged with the precursor molecule dissolved in 
the reaction solvent 
(F) acid vial containing 0.05M HCl for deprotection 
(G) base vial filled with 0.25M NaOH for neutralization 
(H) vacuum pump for solvent removal and 
(I) final product vessel for product isolation. 
The same modular set-up was utilised for each set of experiments using different 
precursor molecules.  
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Figure 3.2: Schematic sketch of the Modular Lab synthetic set-up on the computer with 
A= reaction vial, B= QMA cartridge, C= K222 vial, D= CH3CN vial, E= precursor vial, 
F= acid vial, G= base vial, H= vacuum pump, and I= product vial. 
A flow chart of the automated process performed by the software program is depicted in 
Figure 3.3 below. The automatically driven process consisted of several steps that were 
followed in a consecutive manner. The initial step was the trapping of the fluoride ion 
by the QMA cartridge (B), which was mixed with K222 in vial C and transferred into the 
reaction vial A. Anhydrous CH3CN was injected from vial D into vial A and the mixture 
was azeotropically dried. It is noteworthy that the liquids were transferred automatically 
inside the modular lab through connecting tubes using pressure differences enabled by 
nitrogen gas input. In the next step, the precursor molecule which was dissolved in 1 mL 
of the reaction solvent, was added into vial A from vial E. After the reaction was carried 
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out, the vacuum pump (H) was initialized for 5 minutes to remove the reaction solvent 
at 140 oC. The deprotecting agent was then transferred from vial F into vial A to remove 
the protecting group and neutralized to obtain the crude product. The final step involved 
the preparative HPLC purification of the crude mixture to separate the final product, 
which was to be transferred into vial I.   
 
	  
Figure 3.3: Flow chart describing the general synthetic steps in modular lab. 
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3.1.2.2. [18F]FLT synthesis using 5’-O-Bz-2,3’-anhydrothymidine 
Although a viable method was developed by the Wolfson Molecular Imaging Centre 
group6 using the precursor molecule 5’-O-benzoyl-2,3’-anhydrothymidine, 48 as 
depicted in Scheme 3.4, the experiment was repeated under the same reaction 
conditions to assess the feasibility of the reaction using the modular set-up shown in 
Figure 3.2. 
	  
Scheme 3.4: 18F-FLT synthesis using the precursor 5’-O-Bz-2,3’-anhydrothymidine, 48. 
 
For this procedure, the precursor molecule 5’-O-benzoyl-2,3’-anhydrothymidine, 48 was 
synthesized under Mitsunobu reaction conditions in a one-pot reaction as outlined in 
Scheme 3.5 performing both benzoyl protection at the 5’-O-position and 2,3’anhydro 
ring formation at the 3’-position in one pot.  
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Scheme 3.5: Formation of precursor 48 via Mitsunobu reaction. 
	  
The Modular Lab software program was set up for a reaction time of 10 minutes. All the 
vials in the Modular Lab were filled with 1 mL each of the solutions or solvents as 
mentioned in section 3.1.2.1. The reaction vial (A) was filled with 30 mg of the 
synthesized precursor 48 dissolved and sonicated in 1 mL of anhydrous DMSO. 
Thereafter, the automated radiosynthesis was allowed to proceed by operating the 
Modular Lab software. For the purpose of radiolabeling, 2 GBq of [18F]F- in H218O was 
delivered from the cyclotron into the hot cell containing the Modular synthetic kit and 
passed through the activated QMA ion exchange cartridge (B) to isolate the [18F]F- 
anion. The 18F-fluoride was then passed into vial (C) automatically to complex with the 
Kryptofix [2.2.2] solution and dried azeotropically with dry acetonitrile, after which it 
was transferred into the reaction vial (A). The reaction progress was monitored using 
analytical radio-HPLC with 10% EtOH as the eluent as described in the experimental 
section 6.1.4. In Figure 3.4, the radio-HPLC radioactivity and UV traces of the reaction 
mixture with an activity of 0.89 GBq containing [18F]FLT are given along with the 
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HPLC data of the reference non-radioactive 19F-FLT for comparative study. As seen in 
Figure 3.4, the peak for [18F]FLT was detected at 7.5 minutes and was corresponding to 
the retention time of 19F-FLT. The other peaks detected at UV 254 nm were assigned to 
the following compounds: Kryptofix [2.2.2]/ potassium salts (4.5 to 6.5 minutes), 
elimination product (8.5 to 10 minutes) and thymidine (10 to 10.5 minutes). The 
retention times of thymidine and K222 were analyzed previously with 10% EtOH on 
analytical HPLC. Unfortunately, [18F]FLT could not be purified from the reaction 
mixture by preparative HPLC due to technical issues with the HPLC instrument but the 
formation of [18F]FLT was confirmed by analytical radio-HPLC with a radiochemical 
yield (RCY) of 44.5%. The radioactivity of the crude product was calculated using the 
following equation: 
Bq  =  [moles of 18F- x Na x ln (2)] / t1/2 ; given that 1GBq of Activity = 109 Bq, t1/2 of 
18F= 109.8 minutes, Na = 6.022x1023 mol-1 and ln(2)=0.693. 
RCY (%)  = [radioactivity of the product / starting radioactivity of 18F-]  x 100 
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Figure 3.4: Analytical radioactive and UV (254 nm) HPLC traces of [18F]FLT, 15 
synthesized from precursor 48 compared with UV HPLC trace for reference sample of 
19F-FLT, 10; column : ZORBAX Eclipse Plus C18 (4.6 x 250 mm) 5µm;  
eluent: 10% ethanol in 90% water; flow rate: 1 mL min-1. The main product 15 has been 
labeled in the figure above and is detected at a retention time of 7.5 minutes. 
	  
3.1.2.3. [18F]FLT synthesis using 5’-O-pMeOBz-2,3’-anhydrothymidine 
In continuation of the efforts to develop efficient synthetic methods for [18F]FLT, a 
further improved and similar synthetic approach was sought for the minimization of 
reaction time. Hence the 5’-O-para-methoxybenzoyl-2,3’-anhydrothymidine precursor, 
33 was studied for [18F]FLT radiosynthesis due to the easier removal of the protecting 
group and the novelty of the use of this precursor. Although, the study of fluoridation 
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reactions of this precursor molecule under thermal conditions have not been successful 
as discussed in chapter 2, a positive outcome was still anticipated under radiosynthetic 
conditions to synthesize [18F]FLT, 15. 
The radiosynthesis was performed under the conditions given in Scheme 3.6 using the 
same Modular Lab set up described in the section above. However, the reaction time 
was varied from 5 minutes to 10 minutes and the reaction temperature ranging from 
140oC to 160oC. Therefore, a number of experiments had to be carried out, during which 
technical issues with the Modular Lab kit were encountered. For instance, failure of the 
modular software, electrical faults in the generator connections and formation of 
precipitate causing blockage in modular lab tubes, prompted the experiments to be 
repeated. 
 
 
Scheme 3.6: 18F-FLT synthesis using 5’-O-pMeOBz-2,3’-anhydrothymidine, 33. 
	  
A table of comparison of synthesis yields achieved using different concentrations of the 
precursor molecule 33, in 1 mL of anhydrous DMSO, varying reaction times and 
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temperature is shown below. From Table 3.1, it can be noted that for the reaction to 
become feasible, at the least 30 mg of the precursor 33 had to be used. Another 
observation was that, while undertaking the experiments at a reaction time of 160 oC, 
decomposition of the precursor occurred, which was apparent from the dark brown 
discolouration of the reaction vial (A). Surprisingly, the reaction progressed successfully 
at a reaction temperature of 140 oC within both 5 minutes and 10 minutes of reaction 
time. For the 10 minutes experiment, 2 GBq of activity was used at the start leaving 0.5 
GBq of [18F]-activity at the end and hence RCY of 25%. However, the 5 minutes 
experiment, which started off with 2 GBq of activity as well produced a lower RCY of 
7.1%, presumably due to non-completion of the radio-fluorination reaction. 
 
Table 3.1: Comparison of synthesis yields from different procedures using precursor 33. 
Precursor 
Amount 
(mg) 
Reaction time 
(min) 
Temperature 
(oC) No. of trials 
Reaction 
progress RCY (%) 
160	   1	   X	   /	  
5	  
140	   2	   X	   /	  
160	   1	   X	   /	  
10	  
10	  
140	   1	   X	   /	  
160	   2	   X	   /	  
5	  
140	   3	   X	   /	  
160	   2	   X	   /	  
20	  
10	  
140	   2	   X	   /	  
160	   1	   X	   /	  
5	  
140	   3	   	   7.1	  
160	   2	   X	   /	  
30	  
10	  
140	   3	   	   25	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The reaction mixture was analysed with radio-HPLC using 10% of EtOH as the eluent 
and the formation of trace amounts of [18F]FLT was verified by comparing the data with 
the HPLC data of the reaction mixture sample spiked with reference material, 19F-FLT 
as shown in Figure 3.5. 
 
	  
Figure 3.5: Analytical radioactive and UV (254 nm) HPLC traces of [18F]FLT, 15 synthesized 
from precursor 33 and compared with HPLC traces for [18F]FLT spiked with reference 19F-FLT, 
10. column : ZORBAX Eclipse Plus C18 (4.6 x 250 mm) 5µm; eluent: 10% ethanol in 
90% water; flow rate: 1 mL min-1.  
 
 
 
 
102	  
	  
3.1.2.4. [18F]FLT synthesis using 5’-O-DMTr-2,3’-anhydrothymidine 
Further to the investigation of a suitable method, the next step was to conduct 
experiments using the precursor molecule, 5’-O-Dimethoxytrityl-2,3’-
anhydrothymidine, 37 under the reaction conditions given in Scheme 3.7. However, this 
precursor has been used previously by Machulla and coworkers3 for [18F]FLT synthesis. 
But, due to comparatively longer synthesis times (90-140 min), the study was again 
initiated by variations in some reaction conditions. In the previously studied method, 
anhydrous DMSO was used as the solvent and since the removal of DMSO can take 
longer, it was decided to use anhydrous DMF in order to reduce the overall reaction 
time. As a consequence of the previous experiments conducted at PETIC, led to 
decomposition when the precursor molecule was subjected to the reaction temperature 
of 160 oC, the radiosyntheses were carried out at a maximum reaction temperature of 
140 oC. Also a minimum of 30 mg of the precursor compound, 37 was used in the 
ensuing experiments, which was dissolved and sonicated with 1 mL of anhydrous DMF 
in the reaction vial A. Subsequently, the radiosynthesis experiments were allowed to 
proceed using the Modular Lab synthetic kit with varying reaction times of 5 minutes 
and 10 minutes. Unfortunately, none of the experiments showed satisfactory results as 
the expected product, [18F]FLT peak was not detected using analytical HPLC. This 
could be due to the use of anhydrous DMF as the reaction solvent, which might have 
been less effective than anhydrous DMSO in solvating the precursor molecule 37. 
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Scheme 3.7: Radiosynthetic conditions for [18F]FLT synthesis using precursor 37. 
 
 
3.1.2.5. [18F]FLT synthesis using 5’-O-Tr-3’-nosylthymidine 
At this stage, it was decided to investigate further with the radiosynthesis studies using 
the previously synthesized precursor molecule, 5’-O-trityl-3’-nosyl thymidine, 42. It 
was hoped that the successful synthesis of 19F-FLT from the precursor 42 under 
conventional thermal conditions as discussed in chapter 2, could also have a positive 
impact under radiosynthesis conditions as outlined in Scheme 3.8. Although the 
synthesis of 15 using the precursor 42 has been studied previously and recorded in 
literature (Grierson and Shields method2), the reaction solvent, temperature and 
protecting groups have been varied to conduct a comparative study. The radiosynthesis 
experiments were carried out using the Modular Lab set-up consisting of the reaction 
vial A filled with 30 mg of precursor 42 dissolved in 1 mL of anhydrous DMF. The 
reaction times were varied from 5 minutes to 10 minutes, but the reaction temperature of 
140 oC was kept constant. A number of experiments that were carried out failed due to 
technical issues with the Modular lab kit, such as formation of precipitates in the 
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modular tubes causing blockage and obstructing the automated process. Therefore, the 
radiosynthesis experiments had to be repeated. However, the outcome of these 
experiments were all negative as [18F]FLT peak was not detected after HPLC analysis. 
As it can be noted from the literature, the NH group on thymine base of the precursor 
was masked with a protecting group as the nosyl moiety is a very good leaving group 
and can be easily attacked by the base instead of being substituted by the nucleophile 
18F-. Hence the failure of this experiment can be rationalized by the absence of a suitable 
protecting group on NH.  
	  
	  
Scheme 3.8: Radiosynthesis conditions for [18F]FLT synthesis using precursor 42. 
 
3.1.2.6. [18F]FLT synthesis using 2,3’-anhydrothymidine 
The final set of radiosynthesis experiments were studied using the previously 
synthesized precursor molecule, 2,3’-anhydrothymidine, 44. The particular aspect that 
proved to be advantageous by the use of this precursor 44 is the omission of the 
deprotecting step as the 5’-O-position of the precursor molecule is not protected. Hence, 
the overall reaction time can be reduced. Although the fluoridation reactions performed 
105	  
	  
on the compound 44 under thermal conditions as mentioned in chapter 2, did not result 
in the formation of FLT, it was still agreed to conduct radiosynthesis experiments as the 
reactions are performed in the airtight Eckert-Ziegler modular lab kit enclosed by lead-
shielded hot cell, which would increase the nucleophilicity/ reactivity of the [18F] 
fluoride ion and hence leading to better results. The reaction conditions for the synthesis 
of [18F]FLT using the 2,3’-anhydro precursor are described in Scheme 3.9. 
 
	  
Scheme 3.9: Radiosynthesis conditions for [18F]FLT, 15 synthesis using 2,3’-anhydro 
precursor, 44. 
 
The Modular lab was set up for a reaction time of 5 minutes at the start and all the vials 
were filled accordingly including the reaction vial A with 30 mg of the precursor 
molecule, 44. For the radiolabeling, an activity of 1.2 GBq was available from the 
cyclotron. With the use of the Modular lab software the reaction was allowed to proceed 
under the reaction temperature of 140 oC. At the end of the reaction, the mixture was 
analyzed with radio-HPLC and interestingly the radioactive and UV traces of [18F]FLT, 
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15 were detected as depicted in Figure 3.6. For further verification, the reaction mixture 
was analyzed with reference 19F-FLT sample. 
 
 
Figure 3.6: Analytical radioactive and UV HPLC traces of [18F]FLT compared with HPLC 
traces for [18F]FLT, 15 spiked with reference 19F-FLT, 10. column : ZORBAX Eclipse Plus 
C18 (4.6 x 250 mm) 5µm; eluent: 10% ethanol in 90% water; flow rate: 1 mL min-1.  
 
However, the radiosynthetic yield (RCY) of 1.5 % was very low. Although [18F]FLT 
was detected at a retention time of 7.3 minutes on the analytical HPLC data along with a 
number of unexpected side products, the desired product [18F]FLT could be purified 
using preparative HPLC. Unfortunately, the preparative HPLC could not be operated 
due to faults in the HPLC apparatus and hence purification of the product was not 
pursued. 
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3.1.2.7. Summary of results 
Among the numerous experiments conducted using the previously synthesized precursor 
molecules, only 5’-O-Bz-2,3’-anhydrothymidine, 48, its derivative 5’-O-pMeBz-2,3’-
anhydrothymidine, 33 and 2,3’-anhydrothymidine, 44 gave positive results. Precursor 
molecule 48 gave the highest RCY of 44.5%, while precursor 29 is to be noted for its 
novel use as a precursor for [18F]FLT radiosynthesis. Also the omission of the 
deprotecting step with the use of precursor 44 for [18F]FLT radiosynthesis proved to be 
advantageous due to the reduction in the reaction time. DMF was found to be the 
optimum solvent for the radiolabeling reaction with a reaction temperature of 140 oC. 
The minimum reaction time that could be reduced to, was 5 minutes as further reduction 
in time could lead to incomplete reaction. 
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3.2. Concept of [18F]-FLT ProTides 
In this section, focus is given to the synthetic attempt of novel 18F-incorporated FLT 
phosphoramidates pronucleotides (ProTides) as potential diagnostic PET imaging agents 
that could effectively cross cell membranes and represent a model system to visualize 
the pharmacological and biological effect of these compounds in vivo. The ProTide 
technology is a successful pro-drug strategy developed by Prof. Chris McGuigan and his 
group in 1992 to improve the cellular permeability of biologically active nucleosides 
and thereby improve the bioavailability of nucleoside drugs. The study of FLT ProTides 
as therapeutic agents has been elaborated in chapter 4. The initial stages of the synthesis 
were focussed on converting the 3’-position of the starting material, thymidine, 1 into a 
suitable leaving group (e.g. mesyl) which is labile for nucleophilic attack by the 
fluoride, 18F-; along with the SN2 inversion of stereochemical configuration. The 
expertise of McGuigan group helped to analyze the fact that the phosphoramidate group 
was most likely to be prone to decomposition over multiple synthetic steps involving 
preparative column chromatographic purification. Therefore, the masking of the 5’-OH 
group of thymidine with a phosphoramidate group was carried out during the 
intermediate stages of the synthetic route to generate the ProTide precursor (Scheme 
3.10). Considering the half-life of the radionuclide 18F, the aim was to introduce the 
fluoride 18F- into the 3’-position of the ProTide precursor molecule during the final 
stages of the synthesis. A general description of how ProTide precursor molecules were 
attempted to be synthesized is depicted in Scheme 3.10. All the fluoridation reactions 
were planned to be performed under thermal conditions using different nucleophilic 
fluorides and reaction conditions such as varying temperature and reaction solvents, as 
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the optimization study could lay the framework for translation to 18F-Fluoride 
radiochemistry and eventually the 18F-FLT ProTide radioactive synthesis. 
 
	  
Scheme 3.10: General schematic plan for 18F-FLT ProTide synthesis starting from 
thymidine, 1 converted to β-lyxo thymidine, 49 using methods explained in the next 
section. The thymidine analogue 49 is then protected with phosphoramidate group at 5’-
O-position using standard procedure E (section 6.2), in order to synthesize the ProTide 
precursor. Various reaction conditions have been applied for fluoridation reactions of 
the precursor molecule, which have been detailed in the following sections. 
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3.2.1. Fluoridation attempt via ProTide mesyl precursor 
Initially, 1 was converted to 44 using Mitsunobu reaction conditions as described in 
Scheme 3.11. In order to introduce a hydroxyl group at the 3’-position of the nucleoside 
44, to form the ProTide analogue 50, hydroxylation reaction using NaOH [25M] was 
carried out on 44 to yield the nucleoside 49, which is the epimer of 1. Consecutively, 50 
was synthesized from 49 using the standard procedure E (chapter 6). Unfortunately, the 
incorporation of mesyl group at the 3’-position of 50 to form the ProTide precursor 51 
using mesyl chloride was not successful. It was suspected that mesylation occurred on 
the phosphoramidate group by analyzing with NMR spectrum. Hence, fluoridation 
studies could not be performed on 51 to form the desired compound 52. 
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Scheme 3.11: Synthetic procedure for [18F]FLT ProTide via the mesyl precursor, 51. 
 
	  
3.2.2. Fluoridation attempt via ProTide anhydro precursor 
The next stage was preparing [18F]FLT ProTide 52, using 2,3’-anhydro precursor. As 
the anhydro group has proven to be a good leaving group by the nucleophilic 18F- attack 
in [18F]FLT synthesis, it was anticipated that by generating ProTide anhydro precursor, 
the synthesis of [18F]FLT ProTide could also be achieved by fluoridation. As shown in 
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Scheme 3.12, compound 53 failed to be synthesized from 44 as no reaction occurred 
retaining 100% of the starting material. Although tetrahydrofuran (THF) is the ideal 
solvent for synthesizing ProTides, the reaction was repeated by dissolving compound 44 
in a 1:1 mixture of THF and pyridine as 44 was not dissolving in THF. But a progress in 
reaction could not be observed leading again to the failed attempt of synthesizing 
[18F]FLT ProTides. 
	  
Scheme 3.12: Synthetic attempt of [18F]FLT ProTide, 52 via the anhydro precursor, 53. 
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Chapter 4 
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4.  19F-FLT Phosphoramidates 
	  
4.1. Nucleotide Prodrugs 
Since the discovery of many fluorinated nucleosides and nucleotides with potent anti-
viral and anti-cancer activities, increased attention has been given to their intracellular 
delivery.1 Despite difficult delivery and formulation issues, nucleosides account for a 
large proportion of registered anticancer and antiviral drugs. In general, nucleosides 
become biologically active once they are converted into their respective 5’-O-
triphosphates through three separate nucleoside kinases. However, the initial 
phosphorylation (monophosphorylation) step is usually rate limiting, due to the absolute 
need for nucleoside kinase-mediated activation, and often results in poor 
pharmacokinetic properties for the nucleoside drug candidate that need to be addressed 
during drug development.2 Also, as nucleotides are charged molecules, their membrane 
permeability is very poor and they exhibit low bioavailability. In order to circumvent the 
latter issue and also bypass the conversion of nucleosides into their monophosphates, 
numerous nucleotide prodrug (pro-nucleotide or “ProTide”) strategies have been 
designed, which were found to be effective in successfully delivering nucleotides to 
their intracellular target sites. These approaches involve prodrugs that are designed to 
mask the negatively charged oxygens of the nucleotide analogue 5’-O-monophosphate 
and stabilize it. The diffusion of lipophilic pro-nucleoside analogues across the cell 
membrane occurs through passive diffusion or is facilitated by nucleoside transporters 
which are complex transport systems consisting of multiple carrier proteins.3 Nucleoside 
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transporters play a crucial role for the cellular uptake of nucleoside drugs, which may be 
expressed at various levels for different cell types. Upon entering the cell, the masking 
groups are cleaved to release the monophosphate followed by further intracellular 
phosphorylations as illustrated below to generate the corresponding nucleotide analogue 
triphosphate (Figure 4.1).4,5 Thus the aim of this concept was to synthesize lipophilic 
prodrugs of the nucleoside analogues, which after active transport and enzymatic 
cleavage, release the free monophosphate at high intracellular concentrations. 
 
In this chapter, some of the currently available nucleotide prodrug strategies with a 
particular focus on the aryloxyphosphoramidates of FLT will be discussed. 
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4.2 Nucleotides as Drug Candidates 
	  
In contrast to nucleosides, nucleotides are already phosphorylated species which do not 
require the first enzyme (nucleoside kinase) mediated phosphorylation step for their 
metabolic activation. Therefore, nucleotides possess certain advantages over nucleosides 
considering their amenability as drug candidates. Firstly, nucleotides are expected to 
show activity in cases where the parent nucleoside is inactive due to the poor first 
intracellular phosphorylation as a result of reduced levels of activating enzyme (kinase) 
or reduced transporter-mediated entry of the nucleoside analogue into cells.6 Secondly, 
nucleotides retain activity against certain nucleoside resistant mutants (e.g. HSV TK). 
Another advantage of using nucleotides rather than nucleosides as drugs is in cases 
where nucleosides are metabolically deactivated in vivo due to the actions of certain 
enzymes. For example, nucleosides are often substrates for phosphorylase-induced 
glycosidic bond cleavage, whereas nucleotides are not.7  
After Cohen and Plunkett showed that ara-A monophosphate could enter cells directly 
(albeit poorly)8, the field of nucleotides started to flourish with the discovery by Holy 
and De Clercq of phosphonomethylester nucleosides, a class of nucleotide analogues 
with interesting biological activities.9 
Nucleotides also have some disadvantages over nucleosides as drug candidates. As 
nucleotides are charged species, they possess poor membrane permeability and hence, 
show very poor or no activity in vitro.8 The negative charges of nucleotides also 
contribute to their poor bioavailability10 and instability in biological media as they are 
rapidly dephosphorylated by phosphatases.8 Thus utilizing successful nucleotide 
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prodrug strategies that can potentially overcome these shortages would lead to a better 
generation of antiviral and anticancer drugs. 
 
4.3. Current Pro-nucleotide Strategies 
4.3.1. The Bis (POM) Approach 
The bis (pivaloyloxymethyl) [Bis(POM)] phosphotriester approach, firstly described by 
Farquhar et.al, is one of the possible ways of delivering the nucleotide analogue 
monophosphate derivatives into cells.11-13 The mechanism of release of the nucleotide 
analogue monophosphate is thought to consist of two steps (Figure 4.2). The initial step 
involves an esterase enzyme that cleaves one of the two POM groups to give the highly 
reactive hydroxymethyl phosphotriester, 54 which spontaneously dissociates with the 
elimination of formaldehyde, 55 to give the phosphodiester, 56. The cleavage of the 
second POM group is performed by cellular carboxyesterases resulting in the generation 
of the parent nucleoside monophosphate, 57.14 
But there are numerous issues related to the use of this prodrug strategy. Since the 
esterase enzymes involved in the activation of this class of drugs are present at high 
levels in many tissues including the small intestine, prodrug cleavage prior to absorption 
could limit the oral bioavailability of this class of prodrugs. Also the by-products 
released from the metabolism of bis (POM), i.e. formaldehyde and pivalic acid, are 
relatively toxic. 
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However, this pronucleotide approach has been applied to some antiviral and anticancer 
drugs with variable success. An example is Bis(POM) PMEA (9-(2-
phosphomethoxypropyl)adenine), which is clinically approved for the treatment of HBV 
(VireadTM).15 In addition to that, the application of this strategy to other nucleosides 
including thymidine16 and d4T17 has been reported. 
In terms of anticancer activity, the application of the bis (POM) approach to the 
antitumor active compound 2’-deoxy-5-fluorouridine-5’-monophosphate (FdUMP) was 
found to be useful in inhibiting the growth of cell lines resistant towards the originally 
used nucleoside drug, 5-fluorouracil.18, 19 
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4.3.2. The CycloSal Approach 
While most of the nucleotide prodrugs present to date are activated by enzymes to 
liberate the corresponding nucleotide, some pronucleotide strategies are designed to 
involve chemically driven hydrolysis in their activation process. One such approach is 
the cycloSal method of Meier.20 In this strategy, the cyclosaligenyl (cycloSal) moiety is 
chemically cleaved during the activation, although the second generation of this prodrug 
approach has been designed to also involve esterase cleavage. The metabolism of the 
first generation cycloSal prodrugs to release the attached nucleoside proceeds in two 
consecutive steps, firstly by chemical cleavage of the phenyl phosphotriester, 58 and 
then the benzyl phosphodiester, 59 (Figure 4.3). This concept is based on the different 
stability of the phenyl and benzyl phosphate esters.21 The phenyl ester bond is the most 
labile one among the three P-O bonds, as the negative charge of the departing phenoxide 
ion can be delocalized in the benzene ring. This cleavage leads to the formation of the 2-
hydroxybenzyl phosphodiester, 59. The next step proceeds faster than the prior one 
because the ortho-hydroxy group mesomerically stabilizes the benzocarbocation. This 
would accelerate the formation of the monophosphate, 57 and salicyl alcohol, 60.  
This strategy has been applied to several nucleosides, e.g. d4T22, FdU23, AZT24 and 
PMEA25. In vitro antiviral activity has been shown to correlate with the hydrolytic 
stability of the pronucleotide; 3- and 5-methyl substituents on the benzene ring enhance 
the anti-viral activity against HIV-1 and HIV-2 infected cells. These compounds are 
hydrolytically more stable than their unsubstituted counterparts, which suggest that 
reasonably slow hydrolysis is a prerequisite for markedly increased cellular uptake. The 
methyl substituted compounds also retain their activity in thymidine kinase-deficient 
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cells compared to the unsubstituted cycloSal derivatives. A clear advantage of the first 
generation cycloSal prodrug strategy over esterase-dependant approaches is that no 
potentially toxic side products are liberated upon cleavage. 
 
 
 
4.3.3 The Phosphoramidate Diester Approach 
This particular approach, developed by Wagner et.al., is a prodrug strategy for 
nucleosides where only one of the phosphate charges is masked by an amino acid 
ester.26 This strategy is derived from the pronucleotide method developed by McGuigan 
et.al., in which both phosphate charges are masked to improve cellular uptake.27 The 
unmasked negative charge in the phosphoramidate diester approach contributes to the 
water-solubility and stability of the prodrugs in human blood. The activation proceeds 
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directly to the monophosphate via the action of an enzyme, phosphoramidase, identified 
as Hint-1, without the intermediate action of carboxyesterases (Figure 4.4).28  
This approach has been applied on various nucleosides including d4T29, AZT30 and 
FdU31. Although an improvement in in vitro activity has been observed, in some cases, 
some monoester phosphoramidates had poor bioavailability and underwent a substantial 
degradation to the parent nucleoside in the GI tract.32 
 
 
 
 
4.3.4. The Aryl Phosphoramidate Approach 
This methodology was firstly applied in 1992, when McGuigan et.al used this to 
improve the anti-HIV activity of the nucleoside analogue AZT. Indeed, this approach 
improved significantly the activity of AZT against HIV-1 and HIV-2 in AZT-resistant 
cells. In addition to that, AZT-phosphoramidates were shown to retain full anti-HIV 
activity in cell lines deficient of thymidine kinase whereas AZT failed to do so.33 This 
observation served as a proof of the phosphoramidate ability to overcome the first 
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phosphorylation step, which is the most rate-limiting step for many nucleoside 
analogues with interesting biological profiles. Since then, this strategy has been 
employed to improve the biological activities of nucleoside analogues that are unable to 
efficiently undergo the first phosphorylation step. 
One of the early successes of this pronucleotide phosphoramidate (ProTide) approach 
was observed in the mid 1990s, when a completely inactive nucleoside, 2’3’-
dideoxyuridine (ddU) was turned into an active one, proving that monophosphorylation 
was the rate-limiting step and its triphosphate was active. Thus ddU phosphoramidates, 
61 (Figure 4.5) were found to exert significant anti-HIV activity34, while there was no 
activity seen with the free nucleoside analogue, ddU.35 It is worth noting that the 
antiviral activity of ddU aryloxy phosphoramidates is attributed to the TK1 kinase by-
pass. 
 
                Figure 4.5: The structure of a potent ddU phosphoramidate. 
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These successes led to the application of ProTide technology on a wide range of both 
therapeutic anti-viral and anti-cancer nucleosides with the aim of improving their 
biological activities. Such nucleosides include d4T36 (62), d4A37 (63), ddA37 (64), 2’-
deoxy-2’,2’-difluoro-5-halouridine38 (66) and FUDR39 (65) shown in Figure 4.6. 
Figure 4.6.: Structures of some nucleoside analogues on which ProTide strategy has      
                    been applied. 
 
Structurally, phosphoramidates consist of an aryloxy group and an amino acid 
carboxylic ester moiety, which are both attached to the phosphorus atom, which in turn 
is attached to the 5’-O-position of the nucleoside, as depicted in Figure 4.7. The aryl 
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functionalities in the nucleoside phosphoramidates are either substituted or unsubstituted 
phenyls and naphthyls. Regarding the substitutions in some cases, studies show that 
strongly electron-withdrawing substitutions, e.g. p-CN and p-NO2, lead to slight 
reductions in potency whilst several substitutions, such as p-COOMe, and particularly 
p-Cl groups showed significant potency boosts for some nucleoside analogues 
depending on the SAR (structure-activity relationship) of the nucleoside 
phosphoramidates.40 
 
Figure 4.7: SAR of Aryloxy nucleoside phosphoramidates. 
 
As for the amino acid unit variations and their stereochemistry, great differences in 
activity have been observed in the literature. The amino acid motif is essential for 
sustaining the activity of phosphoramidates as early studies indicated that its 
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replacement with simple n-alkylamines resulted in complete loss of activity. In terms of 
the amino acid stereochemistry, generally L-amino acids seem to give better biological 
results compared to their D-counterparts from conclusion of previous studies.41 
Concerning the ester part, different types of esters have been explored and amongst 
them benzyl ester phosphoramidates were found to be more effective than the other ester 
types from literature studies. Also methyl and ethyl esters gave good results in some 
cases. However, depending on the nucleoside and amino acid ester variables, the 
biological activities also vary.  
The activation of aryloxy phosphoramidates to release the monophosphate species is 
thought to consist of mainly four steps; two of which are enzyme-mediated and the other 
two being spontaneous reactions (Figure 4.8). The activation process is initiated by the 
hydrolytic cleavage of the carboxylic ester moiety hypothesized to be mediated by a 
carboxyesterase – type enzyme. Scientists at Gilead identified cathepsin A as the major 
enzyme responsible for ester cleavage.42 Interestingly, phosphoramidates consisting of 
alanine were found to be bioprocessed quicker than those with branched side chains as 
cathepsin A was found to be less selective towards branched side chain amino acids and 
the reason behind the hydrolyzing selectivity remains unclear. A depiction of the 
mechanistic action involved during these processes for the ProTide of the nucleoside, 
FUDR (5-fluoro-2’-deoxyuridine), 67 is shown in Figure 4.8.39 Upon esterase 
hydrolysis in the second step (b), an intracellular nucleophilic displacement of the 
aryloxy group by the carboxylate anion 68 on the phosphorus centre, takes place 
resulting from the spontaneous formation of a five-membered anhydride ring, 69. In the 
third step (c), the unstable cyclic intermediate opens spontaneously via water mediated 
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hydrolysis to generate the intermediate 70. At this stage, hydrolysis can proceed either 
by attacking the phosphorus atom (Attack 2)44 or the carbonyl function (Attack 1)43. 
However, the hydrolysis often proceeds by the attack of the carbonyl function to release 
the carboxylate. The final activation step (d) is the P-N bond cleavage to generate 
FUDR monophosphate, 71 and this step is believed to result from an intracellular 
activity of the enzyme phosphoramidase.45 
In order for aryloxyphosphoramidates to progress as drug candidates, issues such as by-
product toxicity and stereochemistry should be addressed. The metabolism of 
aryloxyphosphoramidates generates phenol/naphthol aryl derivatives as by-products, 
which are considered to be highly toxic. But it was found that they are not mutagenic. 
Since the phosphorus centre is chiral, often phosphoramidates are synthesized as a 
mixture of diastereoisomers. Although, from a drug development point of view, it is 
very much desired for drugs with chiral centres to be developed as a single stereoisomer 
than a mixture as diastereoisomers often show different biological properties. In this 
case, the phosphorus centre stereogenicity overcomes these issues as both the 
diastereoisomers of the ProTide break down to a single product, which is the nucleotide 
monophosphate.  
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                 Figure 4.8: Proposed activation pathway of FUDR Protides. 
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 4.4 19F-FLT Phosphoramidates/ ProTides	  
	  
In this thesis, mainly the synthesis of unsubstituted phenyloxy/naphthyloxyalanine 
based phosphoramidates of the nucleoside FLT, 10 is focussed on, in order to conduct a 
comparative study of any improvements in the biological properties of FLT. In order to 
obtain a better insight into the mechanism by which FLT acts as a proliferation 
biomarker and to identify novel therapeutic analogues of FLT, the synthesis of lipophilic 
FLT phosphoramidate pronucleotides (ProTides) was carried out that are able to cross 
the cell membranes by passive diffusion and rapidly break down to deliver the 
respective nucleotide monophosphates; hence bypassing the rate-limiting 
monophosphorylation step. A general structure of FLT phosphoramidate is shown in 
Figure 4.9. 
 
Figure 4.9: General structure of FLT phosphoramidates 
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FLT, also known as alovudine in medical terms is a very potent inhibitor of HIV46, 
even more potent than the anti-retroviral agent, AZT. 10 inhibits replication of highly 
NRTI-resistant HIV strains in vitro. However due to safety concerns, the use of 10 as an 
anti-viral agent has been restricted as it exerts toxicity.47 With the insight of improving 
the biological properties of FLT, Prof. McGuigan and group synthesized L-
phenylalaninyl Protides and diamidates prodrugs of FLT as shown in Scheme 4.1 and 
these were tested for anti-viral activity in human T lymphocytes. Unfortunately, the 
prodrugs are less potent than their parent nucleoside, 10 (Table 4.1)48. 
 
Table 4.1: Anti-HIV-1 activity of the protides synthesized in McGuigan laboratory as 
detailed in Scheme 4.1. 
Compound ED50 (µM) TD50 (µM) 
10 0.005 100 
72 0.01 100 
73 0.3 >100 
74 0.3 >100 
75 5 >100 
  
Therefore, the goal of this project was to synthesize new FLT protides with L-Alanine 
esters and unsubstituted aryloxy group (Phenoxy and Naphthoxy) on the phosphorous 
atom as most of the ProTides generated by McGuigan group containing these groups 
exerted improved biological activities over the parent nucleosides. 
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Scheme 4.1: Protides and diamidates prodrugs of FLT, 10, which have been already 
synthesized in the laboratory of Prof. McGuigan.	  
 
Anti-cancer activity of alovudine 10 has not been reported in literature. Therefore the 
anti-viral and anti-cancer activity of FLT and the corresponding ProTides which were 
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going to be synthesized were agreed to be assessed biologically by Prof. Jan Balzarini 
group. 
	  
4.4.1. Synthesis of Phosphorylating Agents 
It is clear from the structure activity relationship studies of phophoramidates, that there 
are mainly three variables that could be changed; the aryl moiety, the amino acid and the 
ester as can be noted from Figure 4.7.  
Literature suggested that most of the aryloxy phosphoramidates consisting of phenyls 
and naphthyls as the aryl moieties showed good pharmacological activities and from 
comparison with all the natural (L) and unnatural (D) amino acids that have been tested 
so far, L-alanine appeared to be the most active in most of the cases. 
Regarding the ester motif variability, benzyl esters seem to be always among the most 
active phosphoramidates, possibly due to the high lipophilicity generated by the 
presence of aromatic groups. Overall several FLT phosphoramidates were synthesized 
with mainly L-alanine as the amino acid, and the aryl moiety being either phenyl or 
naphthyl group with different carboxylic acid ester sidechains in the amino acid. 
For the synthesis of FLT phosphoramidates, it was essential to prepare the 
phosphorylating agents, aryl phosphorochloridates, which were then reacted with FLT. 
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4.4.1.1. Synthesis of Phenyl Phosphorochloridates 
The phenyl phosphorochloridates were synthesized according to the procedures reported 
by McGuigan et al.49 The amino acid ester was used as a hydrochloride salt, of L-
alanine, which was dissolved in anhydrous DCM under an argon atmosphere and cooled 
down to -78 0C after the addition of the commercially available phenyl 
dichlorophosphate in equimolar quantity to the amino acid ester salt. Triethyl-amine 
(two equivalents) was used as the base to trigger the attack of the nucleophilic amine at 
the electrophilic phosphorus (V) center to generate the desired phenyl 
phosphochloridates as represented in Scheme 4.2 below. The amino acid ester salts 
were commercially available with the exception of L-Ala isopropyl ester hydrochloride, 
76 and hence it was synthesized. 
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Scheme 4.2: General mechanism for Aryl L-alanine ester phosphorochloridate   
                                                   synthesis. 
 
After 30 minutes of stirring, the temperature was raised to room temperature and stirred 
for 2-3 hours. The white precipitate side product, triethylammonium chloride salt was 
filtered off after the reaction. The same reaction conditions were adapted for the 
preparation of all the aryl phosphorochloridates. In this case, five different phenyl 
phosphorochloridates were synthesized as listed in Table 4.2. 
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Table 4.2: List of synthesized phenyl L-alanine ester phosphorochloridates. 
Compound Ester (R’) Yield (%) 31P-NMR (ppm) 
in CDCl3 
77 Methyl 50 7.96, 8.15 
78 Ethyl 45 7.84, 8.13 
79 iPropyl 76 8.06, 8.25 
80 tButyl 64 7.96, 8.33 
81 Benzyl 40 7.85, 8.09 
 
Upon the synthesis of these phosphorylating agents, always a 1:1 mixture of 
diastereoisomers was generated due to the non-specificity at the chiral phosphorus 
centre as can be seen from the 31P-NMR data listed in Table 4.2. 
 
4.4.1.2. Synthesis of 1-Naphthyl Phosphorochloridates 
The preparation of 1-naphthyl phosphorochloridates involves the synthesis of 1-
naphthyl dichlorophosphate (82), which is not commercially available unlike the phenyl 
phosphorodichloridate and it is obtained by first dissolving 1-naphthol (1 eq) and 
phosphorus(V)oxychloride in dry ether under argon atmosphere with the successive 
dropwise addition of triethylamine (1 eq) at -78 0C, which again acts as the base to 
promote the nucleophilic attack of the naphthoxide anion at the electrophilic phosphorus 
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(V) center to generate the required intermediate product. The synthesized crude product 
82 was used for the preparation of 1-naphthyl phosphorochloridates without any further 
purification. A similar procedure and mechanism to that used for the preparation of 
phenyl phosphorochloridates, was followed up for synthesizing the five different 1-
naphthyl L-alanine ester phosphorochloridates. 
 
Table 4.3.: List of synthesized 1-Naphthyl L-alanine ester phosphorochloridates 
Compound Ester (R’) Yield (%) 31P-NMR (ppm) 
in CDCl3 
83 Methyl 89 8.06, 8.21 
84 Ethyl 82 8.15, 8.43 
85 iPropyl 75 8.16, 8.35 
86 tButyl 60 8.29, 8.56 
87 Benzyl 55 8.37, 8.65 
 
 
4.4.2.  Synthesis of 19F-FLT Phosphoramidates  
The preparation of FLT ProTides was carried out according to the procedure developed 
by McGuigan et al.49 The prepared nucleoside, FLT (10) (one molar equivalent) was 
first dissolved in anhydrous tetrahydrofuran (THF) under argon atmosphere. 
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Subsequently, the Grignard reagent, tBuMgCl (1.5 - 2 equivalents) was added dropwise 
at room temperature, which acts as the base to abstract the proton from the 5’-OH group 
of the nucleoside. This initiates the nucleophilic attack of the nucleoside at the 
electrophilic phosphorus center of the appropriate aryloxy phosphorochloridate to form 
the respective phosphoramidates as shown in Scheme 4.3. The aim was to prepare FLT 
phosphoramidates from all the prepared phenyl and naphthyl phosphorochloridates, and 
hence generate the respective FLT ProTides. The FLT phosphoramidates were prepared 
with percentage yields ranging from 5-20 % after column purification of the crude 
product as listed in Table 4.4. The final compounds were obtained as a mixture of R and 
S diastereomers at the phosphorus center, which were not separated for final biological 
assays. Once all the phosphoramidates were synthesized and purified, they were 
subjected to biological evaluation for the identification of any potential therapeutic 
activity. 
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Scheme 4.3. General mechanistic pathway for FLT phosphoramidates. 
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Table 4.4 .: Summary of the synthesized FLT phosphoramidates. 
Compound Ar Ester (R’) Yield 
(%) 
31P-NMR 
(ppm) 
in CDCl3 
19F-NMR 
(ppm) 
in CDCl3 
88 Phenyl Methyl 20 3.71, 3.99 -174.94, 
-176.37 
89 Phenyl Ethyl 10 2.54, 2.79 -174.88, 
-175.19 
90 Phenyl iPropyl 13 2.76, 3.55 -174.83, 
-175.18 
91 Phenyl tButyl 5 2.93, 3.82 -175.06, 
-175.15 
92 Phenyl Benzyl 7 2.70, 3.52 -174.86, 
-175.01 
93 Naphthyl Methyl 47 2.95, 3.10 -174.92, 
-175.22 
94 Naphthyl Ethyl 50 3.05, 3.17 -174.93, 
-175.23 
95 Naphthyl iPropyl 22 2.98, 3.14 -174.90, 
-175.19 
96 Naphthyl tButyl 36 3.12, 3.26 -174.85, 
-175.13 
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4.5.    Biological Data  
	  
4.5.1.    Anti-HIV data of FLT-ProTides 
The synthesized FLT phosphoramidates were tested biologically by Balzarini et al in 
human T-lymphocyte (CEM) cells for anti-HIV 1 and anti-HIV 2 activities. The results 
indicated that the compounds exhibited an EC50 ranging from 0.1 to 146 µM which were 
less potent than the parent nucleoside FLT as shown in Table 4.5. However, when 
biological testing was performed in the presence of the thymidine kinase (TK minus) 
enzyme, most of the synthesized compounds retained biological activity, while the 
parent nucleoside showed an EC50 (µM) ≥50.  This confirmed the hypothesis that the 
conversion of FLT into its monophosphate derivative is the rate- limiting step in the 
activation of this nucleoside analogue. In addition, the results proved the success of FLT 
phosphoramidates to be useful in bypassing the first phosphorylation step. Interestingly, 
the data revealed that the phenyl phosphoramidates of FLT had a relatively better 
activity than their naphthyl counterparts. Among them, the ethyl carboxyester ProTide, 
89 showed best activity along with benzyl carboxyester ProTide, 92. 
The compounds were also tested against a broad series of DNA and RNA viruses such 
as Herpes simplex viruses 1 and 2, Vaccinia virus and Vesicular stomatitis virus as 
shown in Table 4.6. Consequently, none of them showed any significant anti-viral 
activity or cytotoxicity. For a reasonable comparison of anti-viral activity, the 
compounds were tested along with some of the predominant anti-viral drugs such as 
Brivudin, Cidofovir, Acyclovir and Ganciclovir. 
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Table 4.5 : Anti-HIV-1 and -HIV-2 data of FLT phosphoramidates 
                   in human T-lymphocyte (CEM) cells. 
     
  EC50 (µM) 
 CEM/0   CEM/TK- 
Compound HIV-1 HIV-2   HIV-2 
88 0.55 ± 0.21 1.3 ± 0.14  4.7 ± 4.8 
89 0.10 ± 0.068 0.24 ± 0.23  1.3 ± 0.71 
90 0.75 ± 0.0 1.1 ± 0.23  28 ± 2.1 
91 0.29 ± 0.16 0.90 ± 0.71  >50 
92 0.13 ± 0.11 0.18 ± 0.049  2.0 ± 0.0 
93 0.43 ± 0.35 0.65 ± 0.35  3.0 ± 1.3 
94 0.16 ± 0.028 0.18 ± 0.071  5.2 ± 0.92 
95 0.56 ± 0.23 1.0 ± 0.27  ≥50 
96 2.3 ± 1.4 4.7 ± 2.4  >50 
10 0.0062 ± 0.0021 0.018 ± 0.014  ≥50 
     
     
EC50 = The effective concentration or concentration required to protect CEM cells 
            against the cytopathogenicity of HIV by 50 % 
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Table 4.6: Cytotoxicity and antiviral activity of compounds in HEL cells  
                  (Human erythroleukemia cell lines).             
       
EC50b (µM) 
Compound 
Minimum 
cytotoxic 
concentrationa 
(µM) 
Herpes 
simplex 
virus-1 
(KOS) 
Herpes 
simplex 
virus-2 
(G) 
Vaccinia 
virus 
Vesicular 
stomatitis 
virus 
Herpes 
simplex 
virus-1   
TK- 
KOS 
ACVr 
88 >100 >100 >100 >100 >100 >100 
89 >100 >100 >100 >100 >100 >100 
90 >100 >100 >100 >100 >100 >100 
91 >100 >100 >100 >100 >100 >100 
92 >100 >100 >100 >100 >100 >100 
93 >100 >100 >100 >100 >100 >100 
94 >100 >100 >100 >100 >100 >100 
95 >100 >100 >100 >100 >100 >100 
96 >100 >100 >100 >100 >100 >100 
10 >100 >100 >100 >100 >100 >100 
Brivudin >250 0.02 112 10 >250 50 
Cidofovir >250 2 1 50 >250 2 
Acyclovir >250 0.4 0.1 >250 >250 10 
Ganciclovir >100 0.03 0.03 >100 >100 4 
       
aRequired to cause a microscopically detectable alteration of normal 
cell morphology. 
 
bRequired to reduce virus-induced 
cytopathogenicity by 50 %.   
   
	  
4.5.2. Anti-tumour data of FLT-ProTides 
The inhibitory effects of the synthesized FLT ProTide compounds on the proliferation 
of murine leukemia cells (L1210), human T-lymphocyte cells (CEM) and human cervix 
carcinoma cells (HeLa) were assessed as presented in Table 4.7. However, the 
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phosphoramidates exerted poor activity as they were 50 to 100 fold less effective than 
the parent nucleoside and they lose activity in TK minus tumour cells. These results 
indicated that the ProTide compounds, which should bypass TK mediated activation, 
appear to have the requirement for TK in order to be active in tumour cells. As TK 
mediated monophosphorylation is the most rate-limiting step, the ProTide analogues 
also exhibited poor anti-tumour activity. 
 
 
Table 4.7: Inhibitory effects of compounds on the proliferation of murine leukemia 
cells (L1210), human T-lymphocyte cells (CEM). 
     
IC50* (µM)  
Compound 
L1210/0 L1210/TK- CEM/0 CEM/TK- 
88 8.2 ± 3.7 > 250 ≥ 250 ≥ 250 
89 4.4 ± 1.4 > 250 ≥ 250 > 250 
90 23 ± 1 220 ± 42 145 ± 38 > 250 
91 6.3 ± 0.6 184 ± 20 124 ± 58 > 250 
92 5.8 ± 0.6 223 ± 39 117 ± 88 172 ± 59 
93 3.0 ± 1.2 110 ± 30 66 ± 10 112 ± 52 
94 6.0 ± 0.9 108 ± 32 81 ± 1 138 ± 5 
95 24 ± 2 176 ± 35 206 ± 62 > 250 
96 36 ± 3 170 ± 30 148 ± 17 > 250 
10 0.081 ± 0.037 176 ± 4 39 ± 26 > 250 
*50% inhibitory concentration. 
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Chapter 5 
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5. Conclusions and Future Perspectives 
 
5.1. Conclusions 
	  
In recent years, 3’-Deoxy-3-[18F]-fluorothymidine (18F-FLT) has been widely 
recognized as a key, specific diagnostic biomarker for tumour cellular proliferation. 
However, many disadvantages have been associated with the current methods for the 
commercial production of [18F]FLT and these include low overall yields and time-
consuming high-performance liquid chromatography (HPLC) purification. These 
disadvantages could be rectified by the development of a fast, efficient synthetic route to 
FLT.  
Initial studies were mainly focussed on the development of a new and efficient chemical 
synthetic route to FLT, 10 under thermal conditions featuring microwave-promoted 
chemistry to accelerate the fluoridation reaction, which then later on can be applied for 
the radiolabeled synthesis of the PET imaging agent, [18F] FLT, 15. It was found that the 
microwave reactions led to decomposition of the precursor molecule under high 
temperature and pressure. Since a high temperature of 140 oC was required for 
fluoridation reactions, further investigations were carried out devoid of microwave 
technology. Hence, precursor molecules with various protecting groups were subjected 
to different fluorides under varying temperatures, reaction solvents and reaction times. 
However, the synthesis of 19F-FLT under thermal conditions using the fluorinating 
agents, TBAF.3H2O, DAST and XtalFluor-M was achieved. 
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Although the thermal fluoridation reactions of the synthesized precursor molecules were 
not all successful, the same synthetic methodologies were extended to the radiosynthesis 
of [18F]FLT using the synthesized precursor molecules. 
Amongst these radiosynthetic experiments, only the precursor molecules with a 2,3’-
anhydro group at 3’-position gave positive results, with precursor molecule 48 giving 
the highest RCY, while precursor 33 is to be noted for its novel use as a precursor for 
[18F]FLT radiosynthesis. Also the omission of the deprotecting step with the use 
precursor 44 for [18F]FLT radiosynthesis proved to be advantageous. DMF was found to 
be the optimum solvent for the radiolabeling reaction with a reaction temperature of 140 
oC. The minimum reaction time that could be reduced to, was 5 minutes, which turned 
out to be expedient in terms of the short-lived radioisotope, 18F (t1/2=110 minutes). 
ProTide analogues of 19F-FLT for therapeutic purpose were prepared by reacting FLT 
with the synthesized phenyl and naphthyl L-alanine phosphorochloridates containing 
different esters using the Grignard reagent, tBuMgCl. Subsequently, biological 
evaluation of the newly developed 19F-FLT ProTide analogues for anti-HIV 1 and anti-
HIV 2 activities were assessed on human T-lymphocyte (CEM) cells. Although the 
results indicated that the synthesized compounds were less potent than the parent 
nucleoside FLT, the analogues retained biological activity in contrast to FLT. This 
proved that the FLT ProTides bypassed the first phosphorylation step. However, the 
therapeutic evaluation for anti-tumour activity on L1210, CEM and HeLa cells showed 
no significant activity. 
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5.2. Recommendations for future work 
	  
Although the biological evaluation results for anti-tumour activity of this particular class 
of FLT ProTides synthesized for this project were not promising, future work could be 
focussed on generating other classes of FLT ProTides by reacting FLT with 
phosphorochloridates containing different ester, amino acid or aryl group.  
It is also worth considering that the study of 18F incorporated FLT ProTides as new 
diagnostic PET imaging agents could be extended by the incorporation of more labile 
leaving groups such as tosyl and nosyl into the 3’-O-position of the phosphoramidate 
protected nucleosides. After a suitable ProTide precursor has been generated, various 
18F-fluoridation studies could be done using different reaction conditions such 
temperature, solvents and precursor concentrations. Once an optimized radioactive 
reaction condition for the most therapeutically interesting FLT ProTide has been 
established, the radiosynthesis of the [18F]FLT ProTide can be carried out. If the 
radiosynthetic studies unfold to be successful, a new class of theragnostic FLT ProTides 
could be generated for the purpose of both therapeutic and diagnostic activity. 
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Chapter 6 
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6. Experimental 
 
6.1. General Experimental Conditions 
6.1.1. Solvents and reagents 
All reagents and solvents were used as supplied from Sigma-Aldrich except thymidine 
and amino acid esters were purchased from Carbosynth. All glassware was oven dried at 
100 0C for several hours or overnight and allowed to cool under a steam of dry nitrogen.  
6.1.2. Thin Layer Chromatography (TLC) 
Thin layer chromatography (TLC) was performed on commercially available Merck 
silica gel 60-F254 pre-coated aluminium plates and separated components were 
visualised using ultra violet light (245 and 366 nm).  
6.1.3. Column Chromatography (CC) 
Column chromatography was performed using Fluka silica (35-70 µM) as stationary 
phase. Glass columns were slurry packed in the appropriate eluant under gravity. 
Samples were applied as a concentrated solution in the same eluant, or pre-absorbed 
onto silica gel. Fractions containing the product were identified by TLC, pooled and the 
solvent removed in vacuo. 
6.1.4. High Performance Liquid Chromatography (HPLC) 
Analytical procedures were run on a high-flow system with radio-, UV (254 nm) and 
refractive index (RI) detectors using a ZORBAX Eclipse Plus C18 (4.6 x 250 mm), 5 
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µm column; elution was performed using a mobile phase consisting of water/ethanol 
(90:10) in gradient. 
6.1.5. Nuclear Magnetic Resonance (NMR) 
1H, 13C, 31P and 19F NMR spectra were recorded on a Bruker Advance 500 MHz 
spectrometer with operating frequencies of 500, 125, 202 and 470 MHz respectively. 
Chemical shifts (δ) were recorded in parts per million (ppm) with tetramethylsilane 
(TMS) as the internal standard for 1H and 13C spectra. 31P-NMR are reported in units of 
d relative to 85% phosphoric acid as external standard, positive shifts are downfield. 
The following abbreviations were used for NMR peak designation; s (singlet), d 
(doublet), t (triplet), q (quartet) and m (multiplet). 
6.1.6. Mass Spectroscopy (MS) 
High and low resolution mass spectroscopy using electroionisation (EI) were run on a 
Waters GCT Premier, and using electrospray (ES) on a Waters LCT Premier XE. Mass 
spectroscopy was performed as a service provided by Cardiff University, School of 
Chemistry. 
6.1.7. Microwave Chemistry 
Microwave synthesis was performed using a CEM Discover Labmate. Temperature was 
measured in situ. 
6.1.8. Melting Points 
Melting points were measured on a Griffen melting point apparatus. 
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6.2. Standard Procedures 
	  
Standard Procedure A: Radiosynthesis of [18F]FLT 
[18F]Fluoride activity (1.5-2 GBq) was transferred from the cyclotron to a 5 ml vial 
fitted with a septum and passed through the QMA cartridge B. Kryptofix [2.2.2] (15 mg, 
40 µmol) and KHCO3 (4% aqueous solution, 75 µL, 30 µmol) were placed in vial C 
containing the [18F]Fluoride solution in anhydrous acetonitrile (1 mL) which was 
transferred automatically from B. The solvents were evaporated under a slight flow of 
nitrogen at 100 oC. A second azeotropic distillation with anhydrous CH3CN (1 mL) was 
performed to remove traces of water. There-after, the appropriate labeling precursor (30 
mg) dissolved and sonicated in the reaction solvent, anhydrous DMSO or DMF (1 mL) 
was added to the reaction vial A and heated at 140 oC for 5-10 minutes. The reaction 
mixture was neutralized by the addition of aq. sodium hydroxide (0.25 M, 0.7 mL) 
solution. 
 
Standard Procedure B: Synthesis of Phosphorodichloridates 
To a stirring solution of phosphorous oxychloride (1 eq) and the appropriate phenol/ 
naphthol (1 eq) under argon atmosphere in anhydrous diethyl ether, was added dropwise 
at -78 0C, anhydrous triethylamine (1 eq). Following the addition, the reaction mixture 
was stirred at -78 0C for 30 min, then allowed to warm up to room temperature. The 
reaction was left for stirring overnight and the formation of the product was monitored 
by 31P-NMR. Once the reaction was complete, the mixture was filtered under nitrogen 
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and the corresponding filterate was concentrated under reduced pressure to give the 
crude product as oil, which was then used in making phosphorochloridates without any 
further purifications. 
 
Standard Procedure C: Synthesis of Aryloxy Phosphorochloridates 
Anhydrous triethylamine (2 eq) was added dropwise after 15 min to a stirring solution 
mixture of the appropriate aryl dichlorophosphate (1 eq) and the appropriate amino acid 
ester salt (1 eq) in anhydrous dichloromethane at -78 0C under argon atmosphere. 
Following the addition, the reaction mixture was stirred at -78 0C for 30 min, then at 
room temperature for 2.5 h. The formation of the product was monitored by 31P-NMR. 
Once the reaction was complete, the solvent was removed under reduced pressure and 
the residue was triturated with dry dietyl ether. The precipitate was filtered under 
nitrogen and the corresponding filterate was concentrated under reduced pressure to give 
the crude product as oil. Most of the synthesized phosphorochloridates were purified by 
flash column chromatography (eluting with ethyl acetate/ petroleum ether, 6:4 v/v). 
 
Standard Procedure D: Synthesis of FLT Phosphoramidates (tBuMgCl method) 
To a stirring solution of FLT (1 eq) in anhydrous THF was added dropwise under argon 
atmosphere, tBuMgCl in 1.0 M THF solution (1.5 eq) and the reaction mixture was 
stirred at room temperature for 30 min. Then a solution of the appropriate 
phosphorochloridate (2 eq) in anhydrous THF was added dropwise to the reaction 
mixture and was left for stirring overnight. The solvent was removed in vacuo and the 
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residue was purified by column chromatography eluting with DCM/MeOH in different 
proportions. The compounds synthesized were generated as a mixture of 
diastereoisomers (PS  and PR) but were unable to be separated. 
 
Standard Procedure E: Synthesis of  Phosphoramidates (NMI method) 
To a stirring solution of nucleoside (1 eq) in anhydrous THF, was added dropwise under 
argon atmosphere NMI (1-methylimidazole, 5 eq). After 15 minutes of stirring, the 
appropriate phosphorochloridate (3 eq) was added dropwise at room temperature and the 
reaction mixture was stirred overnight at room temperature. After monitoring the 
reaction progress by TLC with DCM/ MeOH (9.8:0.2) as the eluent, the solvent was 
removed under reduced pressure. The residue was dissolved in DCM, washed with 
water (twice) and 0.5 N HCl (twice). The organic phase was dried over MgSO4, filtered, 
reduced to dryness and the crude product was purified by column chromatography 
eluting with DCM/ MeOH in different proportions. 
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6.3. Synthesized compounds 
	  
 
5’-O-(4-methoxybenzoyl)-2,3’-anhydrothymidine (33) 
                 
 
                                                         
A mixture containing thymidine, 1 (5.0 g, 20.64 mmol) and triphenylphosphine (12.61 
g, 48.08 mmol, 2.2eq.) was dissolved in DMF (60 mL) and stirred to cool down at 0o C. 
Meanwhile, a solution comprising of DIAD (5.8 g, 28.68 mmol, 5.2 mL, 1.2eq.), 4-
methoxybenzoic acid (3.7 g, 24.32 mmol, 1.1eq.) and DMF (20 mL) was prepared to get 
a yellow solution. This solution was then added drop-wise into the reaction mixture 
maintaining the temperature of 0 oC. Afterwards it was allowed to stir for 1.5 hours at 
room temperature. After that again an aliquot of DIAD (5.5 g, 27.2 mmol, 1.2eq.) and 4-
methoxybenzoic acid (0.5 g, 3.28 mmol) in DMF (10 mL) was added to the reaction 
mixture at 0o C and was left for stirring at room temperature for another 2 hours. Upon 
the second addition of DIAD, a precipitate started to form. After this, the mixture was 
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poured into flask containing ether (400 mL) and stirred for 10 minutes at room 
temperature. The resulting suspension was stored in the fridge at a temperature less than 
4o C for 48 hours. The white amorphous precipitate was collected by filteration and 
washed with ether and brine to give the title compound 33 (6.84 g, 93%) as a fine white 
powder: mp 238-240 0C. 
 
1H-NMR (d6-DMSO): δ 7.87 (2H, d, J = 9Hz, O-Ph), 7.59 (1H, s, H-6), 7.02 (2H, d, J 
= 8.5Hz, O-Ph), 5.92 (1H, d, J = 3.5Hz, H-1’), 5.42 (1H, s, H-3’), 4.58 (1H, m, H-4’), 
4.50 (1H, dd, J =5Hz, J =10Hz, H-5’), 4.33 (1H, dd, J = 6.5Hz, J = 11.5Hz, H-5”), 
3.84 (3H, s, OCH3), 2.62 (1H, m, H-2’), 2.54 (1H, m, H-2”), 1.74 (3H, s, CH3);  
13C-NMR (d6-DMSO): δ 170.9 (C=O), 164.9 (C=O Bz), 163.2 (C-4”), 153.3 (C2), 
136.6 (C6), 131.3 (CH3), 121.2 (C2”), 116.1 (C3”), 113.9 (C1”), 86.8 (C5), 81.9 (C4’), 
77.2 (C3’), 62.3 (C5’), 55.5 (CH3O), 32.7 (C2’) . 
ESI MS m/z (+): Calculated for C18H18N2O6 : 358.1165 found: 381.11 [M+Na]. 
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5’-O-p-methoxybenzoyl-3’-fluoro-3’-deoxythymidine (34) 
  
 
The compound 33 (3.6 g, 10.05 mmol) was dissolved in DMF (30 mL) and stirred to get 
a cloudy solution. Subsequently, cesium fluoride (4.76 g, 31.38 mmol, 3eq.) was added 
to the reaction mixture and was heated to 1200 C under reflux for 24 hours. The resulting 
mixture containing a white precipitate was allowed to cool down to room temperature. 
The precipitate was collected by Buchner filteration, washed with ether and dried to 
give the desired compound, 34 (4.56 g, 91%) as a fine cream powder: mp 208-210 0C;   
1H-NMR (d6-DMSO): δ 7.87 (2H, d, J = 9Hz, o-Ph), 7.59 (1H, s, H-6), 7.02 (2H, d, J = 
8.5Hz, m-Ph), 5.92 (1H, d, J = 3.5Hz, H-1’), 5.42 (1H, s, H-3’), 4.58 (1H, m, H-4’), 
4.50 (1H, dd, J =5Hz, J =10Hz, H-5’), 4.33 (1H, dd, J = 6.5Hz, J = 11.5Hz, H-5”), 
3.84 (3H, s, OCH3), 2.62 (1H, m, H-2’), 2.54 (1H, m, H-2”), 1.74 (3H, s, CH3).  
19F-NMR (d6-DMSO): δ -141.63. 
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5’-O-(4,4’-dimethoxytrityl)-thymidine (35) 
 
 
 
A mixture of thymidine, 1 (0.515 g, 2.126 mmol) and dimethoxytrityl chloride 
(DMTrCl, 0.792 g, 2.339 mmol, 1.1 eq.) was dissolved in anhydrous pyridine (10 mL) 
under inert gas atmosphere and stirred at room temperaure for three hours. The reaction 
mixture was then diluted with ethyl acetate (100 mL) and extracted with copper sulphate 
solution (Cu(II)SO4, 5x25 mL) and brine (50 mL). The yellow-brown solution was dried 
over anhydrous MgSO4 powder and the solvent was evapourated in vacuo. The crude 
product was subjected to preparative column purification using EtOAc:Hexane (7:3, 
v/v) as the eluent to afford the pure title compound, 35 (0.67g, 59%) as a white 
amorphous powder: mp 1190C (lit. mp 119-122 0C)1. 
TLC (ethyl acetate : hexane, 7:3 v/v): Rf = 0.25. 
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 1H-NMR (CDCl3): δ 9.61 (1H, s, NH), 7.63 (1H, s, H-6), 7.41 (6H, m, Ar-H), 6.46 (2H, 
t, Ar-H), 5.35 (1H, s, H-1’), 4.59 (1H, dd, J =3Hz, J = 6Hz, H-3’), 4.10 (1H, d, H-4’), 
3.49 (6H, s, OCH3), 3.39 (1H, dd, J =2.5Hz, J = 10.5Hz, H-5’), 2.47 (1H, m, He-2’), 
2.43 (1H, m, Hx-2’), 1.48 (3H, s, CH3). 
ESI MS m/z (+): Calculated for C31H32N2O7: 544.59 gmol-1, found: 567.55 [M+Na]. 
 
 
 
5’-O-(4,4’-dimethoxytrityl)-2,3’-anhydrothymidine (37) 
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The synthesized compound 35 (0.93g, 1.71 mmol) was weighed into a 50 mL round- 
bottom flask and EtOAc (10 mL) was added to effect dissolution. To this mixture, Ph3P 
(0.69g, 2.63 mmol, 1.5 eq) was added and stirred vigorously. Meanwhile, the solution 
was allowed to cool down to 0 0C and a solution of DIAD (0.5 mL, 2.63 mmol, 1.5 eq) 
in EtOAc (3.3 mL) was prepared and added dropwise to the reaction mixture 
maintaining the temperature between 0-2 0C. Once all the DIAD solution was added, the 
mixture was left for stirring at room temperature for 3 h. Afterwards, the solvent was 
removed using rotary evaporator. Column purification was carried out using EtOAc / 
MeOH mixture (4:1 v/v) containing 0.5% Et3N as the eluent to isolate the product, 37 
(0.63g, 70%) as a white amorphous foam2. 
TLC (EtOAc:MeOH 9:1 v/v): Rf =0.1. 
 
1H-NMR (CDCl3): δ 1.91 (3H, s, CH3), 2.35 (1H, ddd, J = 12.92 Hz, J = 3.8 Hz, J = 
3.04 Hz, H-2’), 2.64 (1H, dd, J = 12.78 Hz, J = 0.86 Hz, H-2”), 3.31 (2H, m, H-5’, H-
5”), 3.77 (6H, s, OMe), 4.32 (1H, m, H-4’), 5.15 (1H, s, H-3’), 5.49 (1H, d, J = 3.8 Hz, 
H-1’), 6.79 (4H, m, ArH), 6.91 (1H, s, H-5), 7.17-7.40 (9H, m, ArH). 
13C-NMR (CDCl3): δ 13.8 (CH3), 34.1 (C-2’), 55.6 (OMe), 62.6 (C-5’), 77.2 (C-3’), 
85.0 (C-4’), 87.2 (C-7), 87.9 (C-1’), 113.6 (ArC), 118.8 (C-5), 127.3-130.4 (ArC), 135.5 
(C-6), 135.8-144.9 (ArC), 153.7 (C-2), 159.0 (ArC), 172.0 (C-4). 
MS (m/z): 549 (M+Na)+, 100%; 1075 (2M+Na)+, 33%. 
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5’-O-(4,4’-dimethoxytrityl)-3’-fluoro-3’-deoxythymidine (36) 
 
 
 
The compound 35 (74 mg, 0.136 mmol) was diluted in a solvent system comprising of 
acetonitrile and methanol in a 1:1 ratio (1.0mL) and CsF (98 mg, 0.64 mmol) was added 
to it. The mixture was heated to 60 0C under reflux and left for stirring overnight. The 
resulting violet slurry was diluted with MeOH and dried under vacuum.3 The obtained 
crude product was subjected to column purification using DCM: MeOH (9.5:0.5) as the 
eluent to form 50 mg of the desired compound, 36 as light violet powder with Rf value 
of 0.38. 
1H-NMR (d4-MeOD): δ 7.71 (1H, s, H-6), 7.41 (6H, m, Ar-H), 6.46 (2H, t, Ar-H), 6.35 
(1H, t, H-1’), 4.56 (1H, dd, J =3Hz, J = 6Hz, H-3’), 4.10 (1H, d, H-4’), 3.75 (6H, s, 
OCH3), 3.39 (2H, m, H-5’, H-5”), 2.47 (1H, m, He-2’), 2.43 (1H, m, Hx-2’), 1.48 (3H, s, 
CH3). 
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19F-NMR (d4-MeOD): δ -150.65. 
 
 
5’-O-(4,4’-dimethoxytrityl)-3’deoxy-2’,3’-didehydrothymidine (39)  
 
 
 
The compound 37 (0.52 g, 0.98 mmol) was dissolved in anhydrous DMF (4 mL) in a 25 
mL round-bottom flask. To this solution, TBAF.3H2O (0.94 g, 2.96 mmol, 3 eq) was 
added and the reaction mixture was heated to 150 0C under reflux conditions. The 
reaction was left to run for 5 hours. After this, the mixture was poured into excess water 
and a white crude precipitate was collected by filteration.3 It was purified by column 
chromatography and a white amorphous powder (50 mg, 10%) was isolated:  
170	  
	  
mp 123-125 0C. 
TLC (DCM:MeOH 9.6:0.4 v/v): Rf =0.27 
 
1H-NMR (CDCl3): δ 1.21 (3H, s, CH3), 3.32 (2H, m, H-5’, H-5”), 3.71 (6H, s, 2x OMe), 
4.95 (1H, br s, H-4’), 6.01 (1H, d, J =3.8 Hz, H-1’), 6.50 (1H, s, H-5), 6.85 (4H, m, 
ArH), 7.21-7.45 (9H, m, ArH). 
 
 
2,3’-anhydrothymidine (44) 
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A mixture of 1 (2 g, 8.26 mmol) and PPh3 (4.33 g, 16.51 mmol, 2 eq) was suspended in 
anhydrous acetonitrile (60 mL) and cooled down to -15 0C in ice-MeOH/Acetone bath. 
To this mixture, DIAD (3.25 mL, 16.51 mmol, 2 eq), which was dissolved in 
acetonitrile (5 mL), was added dropwise maintaining the temperature below -5 0C with 
vigorous stirring. After the addition, the reaction was left to stir for another 5 hours at 0 
0C. Following this, the mixture was again cooled down to -20 0C and was poured into a 
conical flask containing ethyl acetate (100 mL) at the same temperature and stirred for 
15 min. The white precipitate that was formed was collected by Buechner filteration and 
washed with cold ethyl acetate. The obtained compound was again purified by column 
chromatography using DCM-MeOH (8:2 v/v) as the eluent to separate the desired 
product, 44 (0.55 g, 30%): mp 229-230 0C, lit. mp 230 0C.4 
TLC (DCM:MeOH 8:2 v/v): Rf  = 0.30. 
  
1H-NMR (d6-DMSO): δ 1.76 (3H, d, J = 1.1 Hz, CH3), 2.45 (1H, ddd, J1,8 = 19 Hz, J1,4 
=6.7 Hz, J1,2= 3 Hz, H-2”), 2.57 (1H, d, J = 1.2, H-2’), 3.50 (2H, m, H-5’, H-5”), 4.20 
(1H, m, H-4’), 5.03 (1H, t, C-5’OH), 5.25 (1H, br s, H-3’), 5.82 (1H, d, J = 3.9 Hz,  
H-1’), 7.56 (1H, d, J = 1.2 Hz, ArH). 
   
 
 
 
172	  
	  
3’-O-(Methylsulfonyl)-5’-O-trityl-2’-deoxythymidine (40) 
 
 
 
 
 
A dried mixture of thymidine, 1 (4.3 g, 17.75 mmol), trityl chloride (7.4 g, 26.54 mmol), 
and 4-(dimethylamino)pyridine (0.14 g, 1.10 mmol) was dissolved in anhydrous 
pyridine (80 mL) and heated at 80 0C for 8 h. The reaction mixture was then cooled to 0 
0C in an ice bath, and methanesulphonyl chloride (2.75 mL, 35.50 mmol) was added 
dropwise to the reaction flask with constant stirring. The mixture was left for stirring at 
0 0C for 1 h and then kept in the refrigerator overnight. The solvent was removed in 
vacuo, and then 100 mL of ice-water mixture was added to the residue. The resulting 
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aqueous solution was extracted with ethyl acetate (3 x 100 mL). The combined organic 
layer was dried over anhydrous Na2SO4 and concentrated to give the crude product, 
which was purified on a silica gel column using EtOAc/Hexane (1:1, v/v) as eluent to 
give 40 (7.25 g, 73 % ) as a white solid, mp: 121-123 0C, lit. mp: 120-122 0C. 5 
TLC (EtOAc:Hexane, 7:3 v/v): Rf  = 0.45. 
 
1H-NMR (CDCl3): δ 1.48 (s, 3H, CH3), 2.43-2.51 (m, 1H, H-2’), 2.65-2.74 (m, 1H, H-
2”), 3.03 (s, 3H, CH3SO2), 3.45-3.58 (m, 2H, 2 x H-5’), 4.34 (s, 1H, H-4’), 5.42 (m, 1H, 
H-3’), 6.45 (m, 1H, H-1’), 7.29-7.41 (m, 15H, 5’-O-trityl), 7.55 (s, 1H, H-6), 8.48 (s, 
1H, NH). 
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1-(5’-O-Trityl-2’-deoxy-β-D-lyxofuranosyl)thymine (41) 
 
 
 
 
 
NaOH (5.49 g, 137.13 mmol, 10 eq) was added to a solution of compound 40 (7.25g, 
12.89 mmol) in 90% aqueous ethanol (200 mL), and the reaction mixture was refluxed 
for 2 h at 90 0C. Afterwards, the reaction flask containing the mixture was cooled in an 
ice-bath for 15 min and neutralized with 80% acetic acid. The solvent was removed 
under reduced pressure in rotary evaporator. Methanol (100 mL) was added to the 
resulting residue and the pure product 41 (10.55 g, 85%) precipitated out as a white 
powder, which was filtered under vacuum and nitrogen, mp: 241-243 0C, lit. mp: 240-
244 0C. 6 
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1H-NMR (DMSO-d6): δ 1.63 (s, 3H, CH3), 1.84 (d, J = 14.65 Hz, 1H, H-2’), 2.50-2.58 
(m, 1H, H-2”), 3.16-3.42 (m, 2H, H-5’), 4.09 (m, 1H, H-4’), 4.18 (m, 1H, H-3’), 5.22 
(br s, 1H, 3’-OH), 6.12 (d, J = 6.91 Hz, 1H, H-1’), 7.21-7.48 (m, 15H, 5’-O-Trityl), 7.60 
(s, 1H, H-6), 11.28 (br s, 1H, NH). 
13C-NMR (DMSO- d6): δ 12.43 (CH3), 40.76 (C-2’), 63.03 (C-5’), 68.92 (C-3’), 83.21 
(C-1’), 84.11 (C-4’), 86.10 (C-7), 108.30 (C-5), 126.98-128.29 (ArC), 136.75 (C-6), 
150.53 (C-2), 163.84 (C-4). 
 
5’-O-Trityl-3’-deoxy-3’-fluoro-thymidine (43) 
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Method 1: Fluoridation with direct displacement of 3’-OH group 
To a solution of triethylamine trihydrofluoride (TEA.3HF; 1.1 mL, 6.19 mmol, 2eq) in 
anhydrous dichloromethane (20 mL) at room temperature were successively added Xtal 
Fluor-M (1.13g, 4.64 mmol, 1.5 eq) and compound 41 (1.50g, 3.11 mmol, 1eq). The 
reaction mixture was left to stir for 1.5 h. After that, it was quenched with 5% aqueous 
sodium bicarbonate solution (20 mL) and stirred for another 15 min. The resulting 
mixture was extracted twice with DCM. The organic phases were combined and dried 
over anhydrous MgSO4 and filtered. The filterate was concentrated in vacuo and the 
residue was purified on a silica gel column using EtOAc/Hexane (1:1, v/v) as the eluent 
to yield 43 (0.75 g, 50 %) as white foam. 7 
TLC (EtOAc:Hexane, 1:1 v/v): Rf  = 0.5. 
 
Method 2: Fluoridation via Nosyl precursor 
The prepared nosyl precursor 42 (0.15g, 0.22 mmol) was dissolved in anhydrous DMF 
(10 mL) and subsequently a mixture of Tetrabutylammonium fluoride trihydrate 
(TBAF.3H2O; 0.21 g, 0.67 mmol, 3 eq) and Kryptofix [222] (0.12 g, 0.34 mmol, 1.5 eq) 
was added to the reaction flask. The reaction mixture was stirred and heated at 90 0C for 
30 min. After that, the reaction was stopped and the solvent was removed under 
vacuum. Column purification was performed with EtOAc/Hexane (1:1, v/v) as the 
eluent to obtain 43 (0.03 g, 25 %) as white foam.  
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TLC (EtOAc:Hexane, 1:1 v/v): Rf  = 0.5. 
1H-NMR (CDCl3): δ 1.49 (s, 3H, CH3), 2.28-2.45 (m, 1H, H-2’), 2.64-2.75 (m, 1H, H-
2”), 3.41-3.55 (m, 2H, H-5’, H-5”), 4.34 (d, J = 30 Hz, 1H, H-4’), 5.33 (dd, J1,2 = 10 
Hz, J1,3= 52 Hz, 1H, H-3’), 6.51 (m, 1H, H-1’), 7.22-7.45 ( m, 15H, Tr-H), 7.61 (s, 1H, 
H-6), 9.72 (s, 1H, NH). 
19F-NMR (CDCl3): δ -172.95. 
 
1-[5’-O-Trityl-2’-deoxy-3’-O-(4-nitrobenzenesulfonyl)-β-D-threo 
pentofuranosyl]thymine (42) 
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The solid 41 (1.16 g, 2.34 mmol) was dissolved in anhydrous pyridine (20 mL) at 0 0C 
and a mixture of 4-nitrobenzenesulfonyl chloride (Nosyl chloride; 1.06 g, 4.79 mmol, 2 
eq) and silver trifluoromethanesulfonate (1.23 g, 4.79 mmol, 2 eq) was added to the 
solution. The reaction mixture was left for stirring at 0 0C for 50 min. Then the 
temperature was adjusted to room temperature and the reaction was quenched after 40 
min. The mixture was diluted with EtOAc (50 mL) and the precipitate (AgCl) that was 
formed, was filtered. The filterate was extracted with brine (70 mL) and water (70mL). 
The organic layer was dried with anhydrous Na2SO4 and concentrated in vacuo. The 
residue was purified by column chromatography on silica gel with ethyl acetate: hexane 
(4:1, v/v) to give 42 as a yellow solid (1.88 g, 60%), mp: 120-122 0C. 8  
TLC (EtOAc:Hexane, 4:1 v/v): Rf  = 0.8. 
1H-NMR (CDCl3): δ 1.75 (s, 3H, CH3), 2.48 (m, 1H, H-2’), 2.77 (m, 1H, H-2”), 3.21 
(m, 1H, H-5’), 3.59 (m, 1H, H-5”), 4.22 (m, 1H, H-4’), 5.20 (m, 1H, H-3’), 6.23 (m, 1H, 
H-1’), 7.21 (s, 1H, H-6), 7.25 (m, 15H, TrH), 7.89 (d, J = 6.32 Hz, 2H, Ha-Nos), 8.24 
(d, J = 6.32 Hz, 2H, Hb-Nos), 8.71 (s, 1H, NH). 
 
13C-NMR (CDCl3): δ 12.46 (CH3), 39.46 (C-2’), 61.46 (C-5’), 80.28 (C-3’), 81.50 (C-
1’), 84.05 (C-4’), 111.02 (C-5), 124.60 (Nos-C), 127.46-128.86 (Tr-C), 134.82 (C-6), 
150.42 (C-2), 163.35 (C-4). 
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3’-deoxy-3’-fluorothymidine (10) 
 
The compound 43 (0.30g, 0.62 mmol) was dissolved in 80% aqueous acetic acid (10 
mL) and heated at 90 0C for 30 min under reflux. The solvent was removed under 
reduced pressure and the crude product was purified on silica gel column using DCM/ 
MeOH (9.5:0.5 v/v) as eluent to give the desired product, 10 (0.14g, 93%). mp: 176-
1770C, lit. mp: 176 0C. 3 
TLC (DCM: MeOH 9.5:0.5 v/v): Rf = 0.4. 
1H-NMR (d4-MeOD): δ 1.91 (s, 3H, CH3), 2.23-2.62 (m, 2H, H-2’, H-2”), 3.76 (m, 2H 
H-5’, H-5”), 4.27 (dt, J = 35 Hz, 1H, H-4’), 5.01 (bs, 1H, OH), 5.37 (dd, J1,2 = 4.95 Hz, 
J1,3= 50 Hz, 1H, H-3’), 6.32 (m, 1H, H-1’), 7.81 (s, 1H, H-6). 
13C-NMR (d4-MeOD): δ 12.28 (CH3), 39.11 (C-2’), 62.74 (C-5’), 86.82 (J3’,F= 172.8 
Hz, C-3’), 95.24 (C-1’), 96.64 (C-4’), 111.90 (C-5), 137.89 (C-6), 152.42 (C-2), 166.33 
(C-4). 
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19F-NMR (d4-MeOD): δ -176.48. 
 
[18F]- 3’-deoxy-3’-fluorothymidine (15) 
 
 
 
The compound 15 was radiolabeled according to Procedure A from precursor molecules 
48 9, 33 and 44  with RCY of 44.5%, 25% and 1.5 % respectively. 
Radio-HPLC analysis: 
Retention time ([18F]-FLT): 7.5 minutes 
 
 
 
181	  
	  
5’-O-benzoyl-2,3’-anhydrothymidine (48) 
 
 
 
A mixture containing thymidine, 1 (5.0 g, 20.64 mmol) and triphenylphosphine (12.61 
g, 48.08 mmol, 2.2eq.) was dried under Argon, dissolved in DMF (60 mL) and stirred to 
cool down at 0o C. Meanwhile, a solution comprising of DIAD (5.8 g, 28.68 mmol, 5.2 
mL, 1.2eq.), benzoic acid (4.54g, 1.5eq.) and DMF (10 mL) was prepared to get a 
yellow solution. This solution was then added drop-wise into the reaction mixture 
maintaining the temperature of 0 oC. Afterwards it was allowed to stir for 4 hours at 
room temperature. After this, the mixture was poured into flask containing ether (400 
mL) and stirred for 10 minutes at room temperature. The resulting suspension was 
stored in the fridge at a temperature less than 4 oC for 48 hours. The white amorphous 
precipitate was collected by filteration and washed with ether and brine to give the 
compound 48 (5.85 g, 79 %) as a fine white powder. mp: 241-242 oC, lit. mp: 242 oC. 10 
 
182	  
	  
1H-NMR (d6-DMSO): δ 7.87 (2H, d, J = 9Hz, O-Ph), 7.66 (1H, m, O-Ph), 7.59 (1H, s, 
H-6), 7.02 (2H, d, J = 8.5Hz, O-Ph), 5.92 (1H, d, J = 3.5Hz, H-1’), 5.42 (1H, s, H-3’), 
4.58 (1H, m, H-4’), 4.50 (1H, dd, J =5Hz, J =10Hz, H-5’), 4.33 (1H, dd, J = 6.5Hz, J = 
11.5Hz, H-5”), 2.62 (1H, m, H-2’), 2.54 (1H, m, H-2”), 1.74 (3H, s, CH3);  
 
 
 
1-(2-deoxy-β-D-lyxofuranosyl)thymine (49) 
 
 
 
 
A mixture of 44 (0.6 g, 2.67 mmol) and aq. NaOH (1M, 10 mL) was stirred in 
steambath under reflux for three hours. The clear solution changed to gold brown upon 
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heating and the progress of the reaction was monitored by TLC analysis with 
DCM:MeOH (9.5 : 0.5, v/v) as the eluent. The solvent was removed by evaporation 
under reduced pressure.4 The crude compound was purified by column chromatography 
using DCM:MeOH (9.5 : 0.5, v/v) as the eluent to obtain 49 in 57% yield.  
mp: 172-174 oC 
1H-NMR (d6-DMSO): δ 11.25 (1H, s, NH), 7.79 (1H, s, H-6), 6.06 (1H, dd, J = 8.5Hz, 
J= 2.44 Hz, H-1’), 5.25 (1H, d, J = 3.35Hz, 3’-OH), 4.69 (1H, t, J= 5.49 Hz, 5’-OH), 
4.22 (1H, m, H-3’), 3.58-3.82 (3H, m, H-4’, H-5’ and H-5”), 2.55-2.59 (1H, m, H-2”), 
1.84 (1H, dd, J= 14.95 Hz, J= 2.14 Hz, H-2’), 1.76 (3H, s, CH3);  
   
 
1-(5’-O-[benzyl-(methoxy-alaninyl)-phosphate]-β-D-lyxofuranosyl)thymine (50) 
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Prepared according to Procedure E from 49 (2.5g, 10.32 mmol, 1eq), NMI (4.12 mL, 
51.60 mmol, 5 eq) and 77 (8.5 g, 30.62 mmol, 3 eq) in anhydrous THF and pyridine (1:1 
v/v, 50 mL). After addition of the phosphorochloridate 77, the colour of the reaction 
mixture changed from cloudy white to light yellow. Column chromatography 
purification using CHCl3-MeOH (9.8:0.2) as the eluent afforded the product 50 (0.36 g, 
7 %) as oil. 
1H-NMR (CDCl3): δ 7.58 (d, J = 7 Hz, 1H, H-6), 7.35-7.43 (m, 2H, Ar-H), 7.20-7.29 
(m, 3H, Ar-H), 6.25-6.32 (m, 1H, H-1’), 5.22 (m, 1H, 3’-OH), 4.94 (m, 1H, H-3’), 4.31-
4.52 (m, 2H, NH, H-4’), 3.95-4.03 (m, 1H, CH), 3.68 (s, 3H, OCH3), 3.35 (d, J = 16 Hz, 
2H, H-5’, H-5”), 2.48-2.51 (m, 1H, H-2”), 2.09-2.25 (m, 1H, H-2’), 1.85 (d, J = 10 Hz, 
3H, CH3 -Thy), 1.31-1.42 (m, 3H, CH3 -Ala). 
31P-NMR (CDCl3): δ 3.58, 3.71. 
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L-Alanine isopropyl ester hydrochloride (76) 
 
                                           
Thionyl chloride (SOCl2; 16.38 mL, 0.23 mol, 2 eq) was added dropwise at 0 0C to 
isopropyl alcohol (128.9 mL, 1.68 mol, 15 eq) and left to stir. After 30 min under 
stirring, the mixture was allowed to warm to room temperature and L-Alanine (10 g, 
0.12 mol) was added. The reaction mixture was heated at 70 0C under reflux overnight. 
The volatiles were removed under reduced pressure to yield after precipitation with 
diethyl ether, the desired ester hydrochloride salt 76 (25 g, 70%) as a white amorphous 
powder. 
1H-NMR (CDCl3): δ 1.32 (d, J = 6.21 Hz, 6H, 2xCH3 iPr), 1.54 (d, J = 7.19 Hz, 3H, 
CH3 Ala), 4.18 (t, 1H, Hα), 5.12 (m, 1H, CH ester), 8.73 (s, 3H, NH3). 
13C-NMR (CDCl3): δ 15.95 (CH3-iPr), 21.59 (CH3-iPr), 49.34 (CH3-Ala), 70.33 (CH-
ester), 169.51 (C=O). 
 
 
 
186	  
	  
(2S)-methyl-2-(chloro(phenoxy)phosphorylamino)propanoate (77) 
 
 
 
 
The compound 77 was prepared according to Procedure C, from commercially available 
phenyl dichlorophosphate (2.82g, 13.39 mmol, 1.6 mL, 1 eq), L-alanine methyl ester 
hydrochloride salt (1.87 g, 13.30 mmol, 1 eq), and anhydrous triethylamine (2.71 g, 
26.77 mmol, 3.73 mL, 2 eq) in dry DCM (20 mL). The product was obtained as clear oil 
(3.55 g, 50 %). 
31P-NMR (CDCl3): δ 7.96, 8.15. 
1H-NMR (CDCl3): δ 1.52 (m, 3H, CH3-Ala), 3.75 (d, J = 20Hz, 3H, OCH3), 4.21 (m, 
1H, CH), 4.65 (m, 1H, NH), 7.18-7.27 (m, 3H, Ar-H), 7.32-7.39 (m, 2H, Ar-H).        
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(2S)-ethyl-2-(chloro(phenoxy)phosphorylamino)propanoate (78) 
 
 
 
 
The compound 78 was prepared according to Procedure C, from phenyl 
dichlorophosphate (3.17 g, 15.00 mmol, 2.24 mL, 1 eq), L-alanine ethyl ester 
hydrochloride salt (2.30 g, 15.00 mmol, 1 eq), and anhydrous triethylamine (4.20 mL, 
30.00 mmol, 2 eq) in dry DCM (50 mL). The product was obtained as clear oil (3.94 g, 
45 %). 
31P-NMR (CDCl3): δ 7.84, 8.13. 
1H-NMR (CDCl3): δ 1.25 (m, 3H, CH3), 1.51 (m, 3H, CH3), 3.95 (m, 2H, CH2), 4.21 
(m, 1H, CH), 4.53 (m, 1H, NH), 7.21-7.30 (m, 3H, Ar-H), 7.35-7.41 (m, 2H, Ar-H).        
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(2S)-isopropyl-2-(chloro(phenoxy)phosphorylamino)propanoate (79) 
 
 
 
The compound 79 was prepared according to Procedure C, from phenyl 
dichlorophosphate (2.92 g, 13.85 mmol, 2.00 mL, 1 eq), L-alanine isopropyl ester 
hydrochloride salt (76, 2.24 g, 13.85 mmol, 1 eq), and anhydrous triethylamine (3.73 
mL, 26.77 mmol, 2 eq) in dry DCM (50 mL). The product was obtained as clear oil 
(6.21 g, 76 %). 
31P-NMR (CDCl3): δ 8.06, 8.25. 
1H-NMR (CDCl3): δ 1.15-1.25 (m, 6H, 2xCH3-iPr), 1.51 (m, 3H, CH3-Ala), 4.13 (m, 
1H, CH), 4.53 (m, 1H, NH), 5.05-5.12 (m, 1H, CH-iPr), 7.23-7.29 (m, 3H, Ar-H), 7.39-
7.45 (m, 2H, Ar-H).        
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(2S)-tert-butyl-2-(chloro(phenoxy)phosphorylamino)propanoate (80) 
 
 
 
 
The compound 80 was prepared according to Procedure C, from phenyl 
dichlorophosphate (2.92 g, 13.39 mmol, 2.00 mL, 1 eq), L-alanine tert-butyl ester 
hydrochloride salt (2.43 g, 13.39 mmol, 1 eq), and anhydrous triethylamine (3.73 mL, 
26.77 mmol, 2 eq) in dry DCM (50 mL). The product was obtained as clear oil (5.47 g, 
64 %). 
31P-NMR (CDCl3): δ 7.96, 8.33. 
1H-NMR (CDCl3): δ 1.52 (m, 12H, 4xCH3), 4.15 (m, 1H, CH), 4.35 (m, 1H, NH), 7.23-
7.29 (m, 3H, Ar-H), 7.39-7.45 (m, 2H, Ar-H).        
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(2S)-benzyl-2-(chloro(phenoxy)phosphorylamino)propanoate (81) 
 
 
 
 
The compound 81 was prepared according to Procedure C, from phenyl 
dichlorophosphate (2.92 g, 13.39 mmol, 2.00 mL, 1 eq), L-alanine benzyl ester 
hydrochloride salt (2.89 g, 13.39 mmol, 1 eq), and anhydrous triethylamine (3.73 mL, 
26.77 mmol, 2 eq) in dry DCM (60 mL). The product was obtained as clear oil (3.79 g, 
40 %). 
31P-NMR (CDCl3): δ 7.85, 8.09. 
1H-NMR (CDCl3): δ 1.55 (m, 3H, CH3), 4.23 (m, 1H, CH), 4.52 (m, 1H, NH), 5.22 (d, J 
= 15 Hz, 2H, BnCH2), 7.23-7.29 (m, 3H, Ar-H), 7.39-7.49 (m, 7H, Ar-H).        
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1-Naphthyl dichlorophosphate (82) 
 
 
 
Compound 82 was prepared according to Procedure B from 1-naphthol (8.00 g, 55.49 
mmol, 1 eq), POCl3 (8.51 g, 55.49 mmol, 5.18 mL, 1 eq) and anhydrous triethylamine 
(7.73 mL, 55.49 mmol, 1 eq) in dry diethyl ether (120 mL). The product was isolated as 
light yellow oil (15.25 g, 52 %). 
31P-NMR (CDCl3): δ 3.89. 
1H-NMR (CDCl3): δ 7.45-7.59 (m, 4H, H-2, H-3, H-6, H-7), 7.73-7.76 (m, 1H, H-4), 
7.91-7.95 (m, 1H, H-5), 8.12-8.15 (m, 1H, H-8).        
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(2S)-methyl-2-(chloro(naphthalen-1-yloxy)phosphorylamino)propanoate (83) 
 
 
 
The compound 83 was prepared according to Procedure C, from 1-naphthyl 
dichlorophosphate (82, 1.87 g, 7.16 mmol, 1 eq), L-alanine methyl ester hydrochloride 
salt (1.35 g, 7.16 mmol, 1 eq), and anhydrous triethylamine (2.00 mL, 14.33 mmol, 2 
eq) in dry DCM (40 mL). The product was obtained as clear oil (4.18 g, 89 %). 
31P-NMR (CDCl3): δ 8.06, 8.21. 
1H-NMR (CDCl3): δ 1.22 (m, 3H, CH3-Ala), 3.75 (d, J = 45 Hz, 3H, OCH3), 4.21 (m, 
1H, CH), 4.65 (m, 1H, NH), 7.45 (m, 1H, Ar-H), 7.52-7.61 (m, 3H, Ar-H), 7.69-7.72 (d, 
J = 8.5 Hz, 1H, Ar-H), 7.88-7.92 (d, J = 8Hz, 1H, Ar-H), 8.08-8.12 (t, 1H, Ar-H).        
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(2S)-ethyl-2-(chloro(naphthalen-1-yloxy)phosphorylamino)propanoate (84) 
 
 
 
The compound 84 was prepared according to Procedure C, from 1-naphthyl 
dichlorophosphate (82, 1.70 g, 6.51 mmol, 1 eq), L-alanine ethyl ester hydrochloride 
salt (1.00 g, 6.51 mmol, 1 eq), and anhydrous triethylamine (1.32g, 13.03 mmol, 1.82 
mL, 2 eq) in dry DCM (40 mL). The product was obtained as light yellow oil (3.65 g, 82 
%). 
31P-NMR (CDCl3): δ 8.15, 8.43. 
1H-NMR (CDCl3): δ 1.22 (m, 3H, CH3), 1.62 (m, 3H, CH3), 4.12 (m, 1H, CH), 4.20-
4.39 (m, 2H, CH2), 4.55-4.61 (m, 1H, NH), 7.45 (m, 1H, Ar-H), 7.52-7.61 (m, 3H, Ar-
H), 7.69-7.72 (d, J = 8.5 Hz, 1H, Ar-H), 7.88-7.92 (d, J = 8Hz, 1H, Ar-H), 8.08-8.12 (t, 
1H, Ar-H).  
 
194	  
	  
(2S)-isopropyl-2-(chloro(naphthalen-1-yloxy)phosphorylamino)propanoate (85) 
 
 
 
The compound 85 was prepared according to Procedure C, from 1-naphthyl 
dichlorophosphate (82, 1.56 g, 5.97 mmol, 1 eq), L-alanine isopropyl ester 
hydrochloride salt (1.00 g, 5.97 mmol, 1 eq), and anhydrous triethylamine (1.21 g, 11.93 
mmol, 1.67 mL, 2 eq) in dry DCM (40 mL). The product was obtained as light yellow 
oil (3.18 g, 75 %). 
31P-NMR (CDCl3): δ 8.16, 8.35. 
1H-NMR (CDCl3): δ 1.12-1.39 (m, 6H, 2 x CH3), 1.58 (m, 3H, CH3), 4.22 (m, 1H, CH), 
4.55-4.61 (m, 1H, NH), 4.93-5.03 (m, 1H, CH-iPr), 7.45 (m, 1H, Ar-H), 7.52-7.61 (m, 
3H, Ar-H), 7.69-7.72 (d, J = 8.5 Hz, 1H, Ar-H), 7.88-7.92 (d, J = 8Hz, 1H, Ar-H), 8.08-
8.12 (t, 1H, Ar-H).        
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(2S)-tert-butyl-2-(chloro(naphthalen-1-yloxy)phosphorylamino)propanoate (86) 
 
 
 
The compound 86 was prepared according to Procedure C, from 1-naphthyl 
dichlorophosphate (82, 2.16 g, 8.26 mmol, 1 eq), L-alanine tert-butyl ester 
hydrochloride salt (1.50 g, 8.26 mmol, 1 eq), and anhydrous triethylamine (1.67 g, 16.51 
mmol, 2.30 mL, 2 eq) in dry DCM (50 mL). The product was obtained as clear yellow 
oil (3.66 g, 60 %). 
31P-NMR (CDCl3): δ 8.29, 8.56. 
1H-NMR (CDCl3): δ 1.37 (m, 3H, CH3), 1.45 (m, 9H, 3 x CH3), 4.11 (m, 1H, CH), 
4.55-4.61 (m, 1H, NH), 7.45 (m, 1H, Ar-H), 7.52-7.61 (m, 3H, Ar-H), 7.69-7.72 (d, J = 
8.5 Hz, 1H, Ar-H), 7.88-7.92 (d, J = 8Hz, 1H, Ar-H), 8.08-8.12 (t, 1H, Ar-H).        
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(2S)-benzyl-2-(chloro(naphthalen-1-yloxy)phosphorylamino)propanoate (87) 
 
 
 
 
The compound 87 was prepared according to Procedure C, from 1-naphthyl 
dichlorophosphate (82, 2.42 g, 9.27 mmol, 1 eq), L-alanine benzyl ester hydrochloride 
salt (2.00 g, 9.27 mmol, 1 eq), and anhydrous triethylamine (1.88 g, 18.55 mmol, 2.60 
mL, 2 eq) in dry DCM (50 mL). The product was obtained as clear yellow oil (4.12 g, 
55 %). 
31P-NMR (CDCl3): δ 8.37, 8.65. 
1H-NMR (CDCl3): δ 1.56-1.60 (m, 3H, CH3), 4.11-4.15 (m, 1H, CH), 4.65-4.72 (m, 1H, 
NH), 5.17-5.26 (m, 2H, Bn-CH2), 7.45-8.15 (m, 12H, Ar-H).        
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3’-Fluoro-3’-deoxy-5’-O-[benzyl-(methoxy-alaninyl)-phosphate]thymidine (88) 
 
 
 
Prepared according to Procedure D from 10 (0.15g, 0.61 mmol, 1eq), tBuMgCl (1.0M, 
0.11 g, 0.92 mmol, 0.12 mL, 1.5 eq) and 77 (0.34 g, 1.23 mmol, 2 eq) in anhydrous THF 
(15 mL). Column chromatography purification using DCM-MeOH (9.7:0.3) as the 
eluent afforded the title compound 88 (0.12 g, 20 %) as oil. 
1H-NMR (CDCl3): δ 7.58 (d, J = 7 Hz, 1H, H-6), 7.35-7.43 (m, 2H, Ar-H), 7.20-7.29 
(m, 3H, Ar-H), 6.25-6.32 (m, 1H, H-1’), 5.33 (m, 1H, H-3’), 4.31-4.52 (m, 2H, NH, H-
4’), 3.95-4.03 (m, 1H, CH), 3.68 (s, 3H, OCH3), 3.35 (d, J = 16 Hz, 2H, H-5’, H-5”), 
2.48-2.51 (m, 1H, H-2”), 2.09-2.25 (m, 1H, H-2’), 1.85 (d, J = 10 Hz, 3H, CH3 -Thy), 
1.31-1.42 (m, 3H, CH3 -Ala). 
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13C-NMR (CDCl3): δ 175.60 (C=O, Ala), 166.26 (C-4), 152.03-152.28 (C-2), 137.26, 
137.27 (C-6, diastereoisomers), 121.38-130.90 (Ar-C), 112.05, 112.10 (C-5), 94.41-
96.07 (C-4’), 86.55, 86.67 (C-1’), 67.22-67.54 (C-5’), 54.83 (OCH3), 52.83 (CH), 51.66 
(C-3’), 38.68-38.90 (C-2’), 20.25-20.50 (CH3-Ala), 12.54, 12.58 (CH3-Thy, 
diastereoisomers). 
19F-NMR(CDCl3): δ -174.94, -176.37. 
31P-NMR (CDCl3): δ 3.71, 3.99. 
MS (ES-) m/z: 485.05 
Reverse HPLC eluting with H2O/MeOH from 90/10 to 0/100 in 25 min: tR= 17.28 and 
17.96 min (98%). 
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3’-Fluoro-3’-deoxy-5’-O-[benzyl-(ethyloxy-alaninyl)-phosphate]thymidine (89) 
 
 
 
Prepared according to Procedure D from 10 (0.05g, 0.21 mmol, 1eq), tBuMgCl (1.0M, 
0.41 mmol, 0.05 mL, 2 eq) and 78 (0.24 g, 0.82 mmol, 4 eq) in anhydrous THF (10 
mL). Column chromatography purification using DCM-MeOH (9.7:0.3) as the eluent 
generated the final compound 89 (0.02 g, 10 %) as oil. 
 
1H-NMR (CDCl3): δ 8.61 (br s, 1H, NH), 7.58 (s, 1H, H-6), 7.35-7.43 (m, 2H, Ar-H), 
7.20-7.29 (m, 3H, Ar-H), 6.25-6.32 (m, 1H, H-1’), 5.33 (m, 1H, H-3’), 4.43-4.53 (m, 
1H, NH, H-4’), 4.21 (m, 1H, CH), 3.95 (m, 2H, CH2), 3.35-3.51 (m, 2H, H-5’, H-5”), 
2.48-2.51 (m, 1H, H-2”), 2.09-2.25 (m, 1H, H-2’), 1.51 (m, 3H, CH3), 1.25 (m, 3H, 
CH3). 
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13C-NMR (CDCl3): δ 172.50 (C=O, Ala), 163.41 (C-4), 150.17 (C-2), 135.11, 135.07 
(C-6, diastereoisomers), 130.90 –121.38 (Ar-C), 111.49, 111.53 (C-5, diastereoisomers), 
94.29-92.65 (C-3’), 85.11, 84.84 (C-1’, diastereoisomers), 83.11, 82.93 (dd, J= 7.8 Hz, 
C-4’, diastereoisomers), 77.27, 77.02 (C-5’, diastereoisomers), 61.85, 61.82 (OEt, 
diastereoisomers), 50.46, 50.29 (CH Ala, diastereoisomers), 38.18, 37.86 (C-2’, 
diastereoisomers), 21.10, 20.97 (CH3-Ala), 14.10 (OEt), 12.48, 12.36(CH3-Thy, 
diastereoisomers). 
 
19F-NMR(CDCl3): δ -174.88, -175.19. 
31P-NMR (CDCl3): δ 2.54, 2.79. 
MS (ES-) m/z: 499.09 
Reverse HPLC eluting with H2O/MeOH from 90/10 to 0/100 in 25 min: tR= 17.85 and 
18.17 min (97%). 
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3’-Fluoro-3’-deoxy-5’-O-[benzyl-(isopropyloxy-alaninyl)-phosphate]thymidine (90) 
 
 
 
 
Prepared according to Procedure D from 10 (0.07g, 0.29 mmol, 1eq), tBuMgCl (1.0M, 
0.07g, 0.57 mmol, 0.08 mL, 2 eq) and 79 (0.35 g, 1.15 mmol, 4 eq) in anhydrous THF 
(10 mL). Column chromatography purification using DCM-MeOH (9.7:0.3) as the 
eluent generated the desired compound 90 (0.04 g, 13 %) as oil. 
1H-NMR (CDCl3): δ 8.15 (br s, 1H, NH), 7.45 (s, 1H, H-6), 7.35-7.28 (m, 2H, Ar-H), 
7.25-7.15 (m, 3H, Ar-H), 6.51-6.38 (m, 1H, H-1’), 5.35-5.17 (m, 1H, H-3’), 4.51 (m, 
1H, CH iPr), 4.45-4.22 (m, 1H, NH, H-4’), 4.15 (m, 1H, CH Ala), 3.55-3.51 (m, 2H, H-
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5’, H-5”), 2.48-2.51 (m, 1H, H-2”), 2.65-2.49 (m, 1H, H-2’), 1.92 (s, 3H, CH3 Thy), 
1.51 (s, 3H, CH3 Ala), 1.26 (s, 6H, 2xCH3 iPr). 
13C-NMR (CDCl3): δ 173.95 (C=O, Ala), 163.78 (C-4), 150.86 (C-2), 136.11, 136.12 
(C-6, diastereoisomers), 131.90 –122.81 (Ar-C), 110.49, 110.23 (C-5, diastereoisomers), 
94.29, 93.65 (d, J= 7.1 Hz, C-3’, diastereoisomers), 85.12, 84.74 (C-1’, 
diastereoisomers), 83.11, 82.93 (d, J= 7.5 Hz, C-4’, diastereoisomers), 77.27, 77.02 (C-
5’, diastereoisomers), 69.85, 69.82 (CH iPr, diastereoisomers), 50.46, 49.29 (CH Ala, 
diastereoisomers), 38.18, 37.86 (C-2’, diastereoisomers), 21.65, 21.91 (2x CH3-iPr, 
diastereoisomers), 19.95, 20.13 (CH3-Ala), 12.45, 12.32(CH3-Thy, diastereoisomers). 
 
19F-NMR(CDCl3): δ -174.83, -175.18. 
31P-NMR (CDCl3): δ 2.76, 3.55. 
MS (ES-) m/z: 513.12 
Reverse HPLC eluting with H2O/MeOH from 90/10 to 0/100 in 25 min: tR= 18.85 and 
19.17 min (95%). 
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3’-Fluoro-3’-deoxy-5’-O-[benzyl-(tert-butyloxy-alaninyl)-phosphate]thymidine (91) 
 
 
 
Prepared according to Procedure D from 10 (0.08g, 0.33 mmol, 1eq), tBuMgCl (1.0M, 
0.08g, 0.66 mmol, 0.09 mL, 2 eq) and 80 (0.42 g, 1.31 mmol, 4 eq) in anhydrous THF 
(10 mL). Column chromatography purification using DCM-MeOH (9.7:0.3) as the 
eluent generated the title compound 91 (0.02 g, 5 %) as oil. 
1H-NMR (CDCl3): δ 8.68 (br s, 1H, NH), 7.48 (s, 1H, H-6), 7.35-7.28 (m, 2H, Ar-H), 
7.25-7.15 (m, 3H, Ar-H), 6.51-6.38 (m, 1H, H-1’), 5.35-5.17 (m, 1H, H-3’), 4.45-4.22 
(m, 1H, NH, H-4’), 4.15 (m, 1H, CH Ala), 3.55-3.51 (m, 2H, H-5’, H-5”), 2.48-2.51 (m, 
1H, H-2”), 2.65-2.49 (m, 1H, H-2’), 1.92 (s, 3H, CH3 Thy), 1.51 (d, J= 8.5Hz, 3H, CH3 
Ala), 1.46 (s, 9H, 3x CH3 tBu). 
204	  
	  
13C-NMR (CDCl3): δ 174.69 (C=O, Ala), 163.78 (C-4), 150.86 (C-2), 135.09, 135.02 
(C-6, diastereoisomers), 131.90 –122.81 (Ar-C), 110.49, 110.23 (C-5, diastereoisomers), 
94.29, 93.65 (d, J= 7.1 Hz, C-3’, diastereoisomers), 85.12, 84.74 (C-1’, 
diastereoisomers), 83.11, 82.93 (d, J= 7.5 Hz, C-4’, diastereoisomers), 77.27, 77.02 (C-
5’, diastereoisomers), 73.86, 73.02 (C-tBu, diastereoisomers),  50.46, 49.29 (CH Ala, 
diastereoisomers), 38.18, 37.86 (C-2’, diastereoisomers), 27.91, 27.05 (3 x CH3-tBu, 
diastereoisomers) 21.22, 21.08 (CH3-Ala), 12.51, 12.36(CH3-Thy, diastereoisomers). 
 
19F-NMR(CDCl3): δ -175.06, -175.15. 
31P-NMR (CDCl3): δ 3.82, 2.93. 
MS (ES-) m/z: 527.15 
Reverse HPLC eluting with H2O/MeOH from 90/10 to 0/100 in 25 min: tR= 19.55 and 
19.97 min (97%). 
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3’-Fluoro-3’-deoxy-5’-O-[benzyl-(benzoxy-alaninyl)-phosphate]thymidine (92) 
 
 
 
Prepared according to Procedure D from 10 (0.07g, 0.33 mmol, 1eq), tBuMgCl (1.0M, 
0.49 mmol, 0.06 mL, 1.5 eq) and 81 (0.24 g, 0.66 mmol, 2 eq) in anhydrous THF (10 
mL). Column chromatography purification using DCM-MeOH (9.7:0.3) as the eluent 
generated the title compound 92 (0.03 g, 7 %) as oil. 
1H-NMR (CDCl3): δ 8.62 (br s, 1H, NH), 7.49-7.38 (m, 6H, Ar-H + H-6), 7.35-7.28 (m, 
2H, Ar-H), 7.25-7.15 (m, 3H, Ar-H), 6.38-6.25 (m, 1H, H-1’), 5.35-5.17 (m, 3H,CH2Ph 
+ H-3’), 4.45-4.22 (m, 2H, NH + H-4’), 4.15 (m, 1H, CH Ala), 3.55-3.51 (m, 2H, H-5’, 
H-5”), 2.48-2.51 (m, 1H, H-2”), 2.65-2.49 (m, 1H, H-2’), 1.92 (s, 3H, CH3 Thy), 1.51 
(d, J= 8.5Hz, 3H, CH3 Ala). 
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13C-NMR (CDCl3): δ 173.77 (C=O, Ala), 163.78, 163.56 (C-4,diastereoisomers), 
150.86 (C-2), 135.09, 135.02 (C-6, diastereoisomers), 131.90 –122.81 (Ar-C), 110.49, 
110.23 (C-5, diastereoisomers), 94.29, 93.65 (d, J= 7.1 Hz, C-3’, diastereoisomers), 
85.12, 84.74 (C-1’, diastereoisomers), 83.11, 82.93 (d, J= 7.5 Hz, C-4’, 
diastereoisomers), 77.27, 77.02 (C-5’, diastereoisomers), 72.2 (CH2Ph), 50.46, 49.29 
(CH Ala, diastereoisomers), 38.18, 37.86 (C-2’, diastereoisomers), 21.22, 21.08 (CH3-
Ala, diastereoisomers), 12.51, 12.36(CH3-Thy, diastereoisomers). 
 
19F-NMR(CDCl3): δ -174.86, -175.01. 
31P-NMR (CDCl3): δ 3.52, 2.70. 
MS (ES-) m/z: 561.16 
Reverse HPLC eluting with H2O/MeOH from 90/10 to 0/100 in 25 min: tR= 20.64 and 
21.42 min (96%). 
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3’-Fluoro-3’-deoxy-5’-O-[naphthyl-(methoxy-alaninyl)-phosphate]thymidine (93) 
 
 
 
Prepared according to Procedure D from 10 (0.15g, 0.61 mmol, 1eq), tBuMgCl (1.0M, 
0.11 g, 0.92 mmol, 0.12 mL, 1.5 eq) and 83 (0.34 g, 1.02 mmol, 2.5 eq) in anhydrous 
THF (15 mL). Column chromatography purification using DCM-MeOH (9.7:0.3) as the 
eluent afforded the title compound 93 (0.18 g, 47 %) as white foam. 
 
1H-NMR (CDCl3): δ 8.68 (br s, 1H, NH), 8.17-8.14 (m, 1H, Ar-H), 7.89-7.85 (m, 1H, 
Ar-H), 7.71-7.67 (t, J= 8.5 Hz, 1H, Ar-H), 7.58-7.51 (m, 3H, Ar-H + H-6), 7.39-7.25 
(m, 2H, Ar-H), 6.25-6.32 (tt, 1H, H-1’), 5.33-5.05 (m, 1H, H-3’), 4.31-4.52 (m, 2H, NH, 
H-4’), 3.95-4.03 (m, 1H, CH), 3.68 (s, 3H, OCH3), 3.35 (d, J = 16 Hz, 2H, H-5’, H-5”), 
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2.48-2.51 (m, 1H, H-2”), 2.09-2.25 (m, 1H, H-2’), 1.85 (d, J = 10 Hz, 3H, CH3 -Thy), 
1.45-1.32 (m, 3H, CH3 -Ala). 
13C-NMR (CDCl3): δ 175.60 (C=O, Ala), 166.26 (C-4), 152.03-152.28 (C-2), 137.26, 
137.27 (C-6, diastereoisomers), 130.90-126.54 (Ar-C), 125.95-115.67 (Ar-C), 112.05, 
112.10 (C-5), 94.41-96.07 (C-4’), 86.55, 86.67 (C-1’), 67.22-67.54 (C-5’), 51.33, 50.99 
(OCH3, diastereoisomers), 52.83 (CH), 51.66 (C-3’), 38.68-38.90 (C-2’), 20.25-20.50 
(CH3-Ala), 12.54, 12.58 (CH3-Thy, diastereoisomers). 
 
19F-NMR(CDCl3): δ -174.92, -175.22. 
31P-NMR (CDCl3): δ 2.95, 3.10. 
MS (ES-) m/z: 535.12 
Reverse HPLC eluting with H2O/MeOH from 90/10 to 0/100 in 25 min: tR= 22.14 and 
22.42 min (98%). 
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3’-Fluoro-3’-deoxy-5’-O-[naphthyl-(ethoxy-alaninyl)-phosphate]thymidine (94) 
 
 
 
Prepared according to Procedure D from 10 (0.10g, 0.42 mmol, 1eq), tBuMgCl (1.0M, 
0.62 mmol, 0.08 mL, 1.5 eq) and 84 (0.35 g, 1.02 mmol, 2.5 eq) in anhydrous THF (10 
mL). Column chromatography purification using DCM-MeOH (9.7:0.3) as the eluent 
generated the final compound 94 (0.15 g, 50 %) as white foam. 
 
1H-NMR (CDCl3): δ 8.68 (br s, 1H, NH), 8.17-8.14 (m, 1H, Ar-H), 7.89-7.85 (m, 1H, 
Ar-H), 7.71-7.67 (t, J= 8.5 Hz, 1H, Ar-H), 7.58-7.51 (m, 3H, Ar-H + H-6), 7.39-7.25 
(m, 2H, Ar-H), 6.25-6.32 (tt, 1H, H-1’), 5.33 (m, 1H, H-3’), 4.43-4.53 (m, 1H, NH, H-
4’), 4.21 (m, 1H, CH), 3.95 (m, 2H, CH2), 3.35-3.51 (m, 2H, H-5’, H-5”), 2.48-2.51 (m, 
1H, H-2”), 2.09-2.25 (m, 1H, H-2’), 1.51 (m, 3H, CH3), 1.25 (m, 3H, CH3). 
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13C-NMR (CDCl3): δ 175.60 (C=O, Ala), 166.26 (C-4), 152.03-152.28 (C-2), 137.26, 
137.27 (C-6, diastereoisomers), 130.90-126.54 (Ar-C), 125.95-115.67 (Ar-C), 111.49, 
111.53 (C-5, diastereoisomers), 94.29-92.65 (C-3’), 85.11, 84.84 (C-1’, 
diastereoisomers), 83.11, 82.93 (dd, J= 7.8 Hz, C-4’, diastereoisomers), 77.27, 77.02 
(C-5’, diastereoisomers), 61.85, 61.82 (OEt, diastereoisomers), 50.46, 50.29 (CH Ala, 
diastereoisomers), 38.18, 37.86 (C-2’, diastereoisomers), 21.10, 20.97 (CH3-Ala), 14.10 
(OEt), 12.48, 12.36(CH3-Thy, diastereoisomers). 
 
 
19F-NMR(CDCl3): δ -174.93, -175.23. 
31P-NMR (CDCl3): δ 3.05, 3.17. 
MS (ES-) m/z: 549.16 
Reverse HPLC eluting with H2O/MeOH from 90/10 to 0/100 in 25 min: tR= 22.24 and 
22.65 min (98%). 
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3’-Fluoro-3’-deoxy-5’-O-[naphthyl-(isopropoxy-alaninyl)-phosphate]thymidine 
(95) 
 
 
 
 
Prepared according to Procedure D from 10 (0.10g, 0.42 mmol, 1eq), tBuMgCl (1.0M, 
0.61 mmol, 0.08 mL, 1.5 eq) and 85 (0.35 g, 1.15 mmol, 2.3 eq) in anhydrous THF (10 
mL). Column chromatography purification using DCM-MeOH (9.7:0.3) as the eluent 
generated the desired compound 95 (0.04 g, 22 %) as oil. 
1H-NMR (CDCl3): δ 8.68 (br s, 1H, NH), 8.17-8.14 (m, 1H, Ar-H), 7.89-7.85 (m, 1H, 
Ar-H), 7.71-7.67 (t, J= 8.5 Hz, 1H, Ar-H), 7.58-7.51 (m, 3H, Ar-H + H-6), 7.39-7.25 
(m, 2H, Ar-H), 6.25-6.32 (tt, 1H, H-1’), 5.35-5.17 (m, 1H, H-3’), 4.51 (m, 1H, CH iPr), 
4.45-4.22 (m, 1H, NH, H-4’), 4.15 (m, 1H, CH Ala), 3.55-3.51 (m, 2H, H-5’, H-5”), 
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2.48-2.51 (m, 1H, H-2”), 2.65-2.49 (m, 1H, H-2’), 1.92 (s, 3H, CH3 Thy), 1.51 (s, 3H, 
CH3 Ala), 1.26 (s, 6H, 2xCH3 iPr). 
13C-NMR (CDCl3): δ 175.60 (C=O, Ala), 166.26 (C-4), 152.03-152.28 (C-2), 137.26, 
137.27 (C-6, diastereoisomers), 130.90-126.54 (Ar-C), 125.95-115.67 (Ar-C), 110.49, 
110.23 (C-5, diastereoisomers), 94.29, 93.65 (d, J= 7.1 Hz, C-3’, diastereoisomers), 
85.12, 84.74 (C-1’, diastereoisomers), 83.11, 82.93 (d, J= 7.5 Hz, C-4’, 
diastereoisomers), 77.27, 77.02 (C-5’, diastereoisomers), 69.85, 69.82 (CH iPr, 
diastereoisomers), 50.46, 49.29 (CH Ala, diastereoisomers), 38.18, 37.86 (C-2’, 
diastereoisomers), 21.65, 21.91 (2x CH3-iPr, diastereoisomers), 19.95, 20.13 (CH3-Ala), 
12.45, 12.32(CH3-Thy, diastereoisomers). 
 
19F-NMR(CDCl3): δ -174.90, -175.19. 
31P-NMR (CDCl3): δ 2.98, 3.14. 
MS (ES-) m/z: 563.65 
Reverse HPLC eluting with H2O/MeOH from 90/10 to 0/100 in 25 min: tR= 22.29 and 
22.78 min (97%). 
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3’-Fluoro-3’-deoxy-5’-O-[naphthyl-(tert-butoxy-alaninyl)-phosphate]thymidine 
(96) 
 
 
 
 
 
Prepared according to Procedure D from 10 (0.10g, 0.42 mmol, 1eq), tBuMgCl (1.0M, 
0.62 mmol, 0.08 mL, 1.5 eq) and 86 (0.30 g, 0.82 mmol, 2 eq) in anhydrous THF (10 
mL). Column chromatography purification using DCM-MeOH (9.7:0.3) as the eluent 
generated the title compound 96 (0.08 g, 36 %) as oil. 
1H-NMR (CDCl3): δ 8.68 (br s, 1H, NH), 8.17-8.14 (m, 1H, Ar-H), 7.89-7.85 (m, 1H, 
Ar-H), 7.71-7.67 (t, J= 8.5 Hz, 1H, Ar-H), 7.58-7.51 (m, 3H, Ar-H + H-6), 7.39-7.25 
(m, 2H, Ar-H), 6.25-6.32 (tt, 1H, H-1’), 5.35-5.17 (m, 1H, H-3’), 4.45-4.22 (m, 1H, NH, 
H-4’), 4.15 (m, 1H, CH Ala), 3.55-3.51 (m, 2H, H-5’, H-5”), 2.48-2.51 (m, 1H, H-2”), 
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2.65-2.49 (m, 1H, H-2’), 1.92 (s, 3H, CH3 Thy), 1.51 (d, J= 8.5Hz, 3H, CH3 Ala), 1.46 
(s, 9H, 3x CH3 tBu). 
13C-NMR (CDCl3): δ 174.70 (C=O, Ala), 166.26 (C-4), 152.03-152.28 (C-2), 137.26, 
137.27 (C-6, diastereoisomers), 130.90-126.54 (Ar-C), 125.95-115.67 (Ar-C), 110.49, 
110.23 (C-5, diastereoisomers), 94.29, 93.65 (d, J= 7.1 Hz, C-3’, diastereoisomers), 
85.12, 84.74 (C-1’, diastereoisomers), 83.11, 82.93 (d, J= 7.5 Hz, C-4’, 
diastereoisomers), 77.27, 77.02 (C-5’, diastereoisomers), 73.86, 73.02 (C-tBu, 
diastereoisomers),  50.46, 49.29 (CH Ala, diastereoisomers), 38.18, 37.86 (C-2’, 
diastereoisomers), 27.91, 27.05 (3 x CH3-tBu, diastereoisomers) 21.22, 21.08 (CH3-
Ala), 12.51, 12.36(CH3-Thy, diastereoisomers). 
 
19F-NMR(CDCl3): δ -174.85, -175.13. 
31P-NMR (CDCl3): δ 3.12, 3.26. 
MS (ES-) m/z: 577.22 
Reverse HPLC eluting with H2O/MeOH from 90/10 to 0/100 in 25 min: tR= 23.29 and 
23.78 min (99%). 
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